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1 Introduction 
Cancer is the second leading cause of death in Germany following the cardiovascular system 
diseases. Head and neck cancers (HNC) account for circa 6% of total cancer incidences in 
Germany (Koch Institute and Centre for Cancer Registry Data, 2009) and it is the sixth most 
common cancer worldwide (Curado and Hashibe, 2009; Braakhuis et al., 2010). Head and 
neck cancers include cancers in oral, nose, and throat cavities as well as in the laryngeal 
region, and around 90% are squamous cell carcinomas (head and neck squamous cell car-
cinoma, HNSCC) (Curado and Hashibe, 2009; Koch Institute and Centre for Cancer Registry 
Data, 2009; Braakhuis et al., 2010). Heavy alcohol consumption and smoking are the primary 
exogenous factors leading to HNC. Treatment choices of HNSCC primarily depend on the 
stage of the disease. For high grade HNSCC, tumors are generally treated with multimodal 
therapies consisting of surgical removal and mostly adjuvant radio(chemo)therapy (Langer, 
2008). Due to tumor heterogeneity and intrinsic radiation sensitivity, an advanced tumor 
stage is often accompanied by therapy resistance, enhanced normal tissue toxicity due to 
intensified therapies and a higher probability of recurrence. In the last 30 years, despite novel 
therapeutic approaches and advances in the understanding of genetics and molecular 
mechanisms underlying HNSCC, overall survival and progression-free survival of patients 
with HNSCC were only minimally improved (Greenlee et al., 2001; Langer, 2008). 
In order to overcome resistance to therapy and to enhance treatment success, it remains 
urgent to discover new treatment approaches. One possible strategy is the inhibition of new 
target molecules to sensitize tumors to standard therapies (Cordes et al., 2013; Eke and 
Cordes, 2015). Prerequisite for this therapeutic approach is the basic understanding of tumor 
biology and the unique properties that make tumor cells different from non-tumor cells. 
Hanahan and Weinberg described such unique properties for malignant tumors as "Hall-
marks of Cancer" (Hanahan and Weinberg, 2011). These include: (1) maintenance of prolif-
erative signaling pathways; (2) inhibition of growth suppressors; (3) activation of invasion and 
metastasis; (4) resistance to cell death (e.g. apoptosis); (5) enabling replicative immortality; 
and (6) genome instability and mutations. 
Focal adhesion proteins (FAPs) and extracellular matrices have been recently defined 
as important modulators of the Hallmarks of Cancer and their significant role in therapy re-
sistance (Ganguly et al., 2013; Glukhova and Streuli, 2013; Marelli et al., 2013; Pickup et al., 
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2014; Eke and Cordes, 2015; Dickreuter et al., 2016). By binding to extracellular matrix pro-
teins, FAPs activate intracellular signaling cascades to regulate survival, proliferation, apop-
tosis, invasion and metastasis (Hynes, 2002; Brakebusch and Fässler, 2005; Hehlgans et al., 
2007). A growing number of (pre-)clinical studies reported the importance of FAPs and 
transmembrane receptors (e.g. β1 integrin, FAK, AKT, EGFR, VEGFR, etc.) for cell survival 
through the activation of intracellular signaling pathways. In vitro and in vivo experiments with 
HNSCC and breast carcinomas showed the inhibition of FAPs lead to sensitization of the 
tumors to radiotherapy and chemotherapy by the inactivation of key pro-survival signaling 
pathways (Cordes et al., 2006; Park et al., 2008; Eke et al., 2012). However, the role of FAPs 
in the repair of DNA double-strand breaks (DSB) induced by radiation is largely unknown. 
Dickreuter and colleagues identified β1 integrin as mediator of DNA repair processes through 
the regulation of key DNA repair proteins such as Ku70, Ku80 and DNA-PKcs. In addition, 
accumulating evidences suggested that cytoplasmic FAP signaling is associated with nuclear 
repair dynamics through interactions between the pro-survival non-receptor tyrosine kinases, 
such as c-Abl, and components of the DNA repair machinery, including DNA-PKcs, ATM, 
BRCA1 and RAD51 (Jin et al., 1997; Hantschel and Superti-Furga, 2004; Ren, 2005; Shaul 
and Ben-Yehoyada, 2005). 
In this thesis, the influence of FAP-mediated signaling pathways on the repair of radia-
tion-induced DSB and the underlying molecular mechanisms were investigated. 
A 3D high-throughput RNA interference screen (3D-HTP-RNAi-S) of 117 FAPs was 
performed identifying synemin as the main target. The functions of synemin in HNSCC cell 
survival and therapy resistance was explored uncovering its molecular mechanism involved 
in DNA repair. It was discovered that synemin inhibition reduces non-homologous end joining 
(NHEJ) activity and enhances cellular sensitivity to radiochemotherapy. Mechanistically, 
synemin affects the phosphorylation status of DNA-PK S2056 and also Ku70 protein levels 
after irradiation. Furthermore, synemin regulates tyrosine kinases upon X-ray exposure. C-
Abl, a key tyrosine kinase involved in many pro-survival mechanisms, is highly dependent on 
synemin expression. Moreover, the here discovered protein complex formed between DNA-
PKcs, c-Abl, and synemin was shown to be dependent on ATM kinase activity and inevitable 
for cell survival and DNA repair. In conclusion, synemin is required for prosurvival DNA repair 
signaling and the regulation of NHEJ in an ATM dependent manner. Our study provides evi-
dence of cytoarchitectural elements such as intermediate filaments as key co-regulators of 
nuclear DNA repair. 
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2 Background 
2.1 Extracellular matrix, adhesion mediated radiation resistance 
and 3D cell culture model 
The extracellular matrix (ECM) surrounds cells in order to provide structural and biochemical 
support and organizes multicellular complexes into tissues. It is possible to distinguish two 
subtypes of ECM: the basement membrane, a condensed 1-layer matrix adjacent to epitheli-
al cells, and the interstitial matrix, which surrounds the cells in the connective tissue (Bosman 
and Stamenkovic, 2003; Frantz et al., 2010). 
The ECM comprises two classes of macromolecules: polysaccharide chains and fibril-
lar proteins. The polysaccharide chains are covalently bound to transmembrane proteins and 
together they form proteoglycans. The fibrillar proteins such as collagen, fibronectin, elastin, 
and laminin have a structural function and additionally serve as ligands for the adhesion mol-
ecules of cells. The proteoglycans form a gel-like structure in which the fibrillar proteins are 
embedded. Mesenchymal cells such as fibroblasts are in charge of producing and secreting 
ECM proteins (Bosman and Stamenkovic, 2003; Kalluri, 2003; Guo and Giancotti, 2004; 
Frantz et al., 2010). 
The ECM is not static, comprising growth factors, cytokines, or hormones, and it is 
constantly reorganized. For example, the conformation of the ECM drastically changes dur-
ing development, aging, and tumor progression. Also, processes such as re-synthesis or the 
proteolytic degradation by matrix metalloproteinases (MMPs) play an important role in re-
structuring the ECM (Labat-Robert, 2003; Mott and Werb, 2004). 
The ECM not only ensures the stabilization of cells in the tissue but also maintains tis-
sue integrity. Through the adhesion of cells to ECM proteins, different cytoplasmic signaling 
pathways become activated, leading to regulation of cellular processes such as survival, mi-
gration, development, and proliferation (Bosman and Stamenkovic, 2003; Kalluri, 2003; Guo 
and Giancotti, 2004; Frantz et al., 2010). Integrins are an essential group of the ECM adhe-
sion molecules. Reorganization of the ECM drives changes in the integrin-mediated signaling 
pathways and thus different cell processes are affected. This modulation of integrin-
dependent signaling pathways by the ECM restructuring is, on one hand, required for devel-
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opment, but is also fundamental for tumor development and response to chemo- and radio-
therapy (WERB and CHIN, 1998; Larsen et al., 2006; Eke and Cordes, 2011b; Eke and 
Cordes, 2011a). 
For instance, it has been demonstrated that cells cultured on matrices containing ECM 
proteins are more resistant to radiation or/and chemotherapy than the ones cultured on plas-
tic. These mechanisms are referred to as cell adhesion-mediated radioresistance (CAM-RR) 
and cell adhesion-mediated drug resistance (CAM-DR) (Damiano et al., 1999; Cordes and 
Meineke, 2003). Both normal cells such as human fibroblasts and keratinocytes, as well as 
glioblastoma tumor cells, pancreatic carcinomas, bronchial carcinomas, melanomas, and 
breast cancers, have increased resistance to radiation after growth on fibronectin or laminin 
in comparison to cells cultured on plastic (Cordes et al., 2003; Cordes and Meineke, 2003). 
Prof. Cordes’ group was able to show that the cytotoxicity and radiation sensitization of 
the EGFR (epidermal growth factor receptor) inhibitor cetuximab decreases when cells ad-
here to fibronectin. Cetuximab treatment leads to activation of p38 MAPK (mitogen-activated 
protein kinase p38) / ATF2 (cyclic AMP-dependent transcription factor ATF-2) for fibronectin 
synthesis and secretion (Eke, Schneider et al., 2013; Eke, Storch et al., 2013). 
The studies listed above were carried out under 2D monolayer growth conditions coat-
ed with ECM proteins. However, 3D models in which the cells are embedded in a laminin-rich 
ECM reflect better the physiological situation of cells in tissues (Storch et al., 2010; Eke and 
Cordes, 2011). Various studies provide strong evidence that gene and protein expression as 
well as survival, proliferation, and differentiation are significantly influenced when cells are 
grown under 3D conditions (Roskelley et al., 1994; Le Beyec et al., 2007; Lelièvre, 2009; 
Zschenker et al., 2012). Comparative transcriptome and proteome analyses show that 3D 
ECM-based cell culture is highly similar to the in vivo situation (Fig. 2.1) (Petersen et al., 
1992). While cells grown on plastic present a stretched-out actin cytoskeleton and flat mor-
phology, 3D-cultured cells, through the interaction with the ECM, exhibit a rounded morphol-
ogy similar to cells in vivo (Yamada and Cukierman, 2007; Eke and Cordes, 2011). Storch et 
al. have shown that cells grown under 3D conditions, compared to 2D, express an increased 
proportion of heterochromatin and as a result present less radiation-induced DSBs, leading 
to increased radiation resistance (Storch et al., 2010). 
Because the 3D ECM-based cell culture models the in vivo situation, it is more suitable 
as a predictive in vitro assay to evaluate tumor response to therapy. In addition, novel mo-
lecular targets can be more clinically relevant and translational when tested in 3D ECM-
based cell cultures. For the investigations carried out in this work on the role of FAPs in radi-
ation-induced DSB repair, cells were cultured under 3D conditions in a laminin-rich ECM also 
termed lrECM (MatrigelTM), which is similar to the ECM underlying the epithelium and thus 
mimics the in vivo situation (Bissell et al., 2005; Storch et al., 2010). 
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Figure 2.1: Comparison of 2D and 3D cell culture conditions. Cells cultivated under 2D conditions show a flat 
morphology. Cells embedded in a 3D microenvironment exhibit a rounded morphology similar to the in vivo situa-
tion. 
2.2 Integrins and focal adhesion proteins (FAPs) 
For multicellular structures or tissues to be formed, cells must interact via cell-cell contacts 
and across adhesion transmembrane receptors, such as integrins, which anchor in the ECM. 
Integrins, together with large protein complexes, form the focal adhesion (FA) plaques, which 
anchor on extracellular proteins. 
Integrins are heterodimers and consist of an α- and β-subunit, which are linked by non-
covalent bonds. There are 18 α- and 8 β-subunits known, from which 24 different integrin 
receptors can be formed. The combination of the α and β subunits determines the binding 
specificity of the integrin (Hynes, 2002). In brief, integrins have one large extracellular ecto-
domain, a transmembrane domain, and a short cytoplasmic tail. Most integrins are not con-
stitutively active and are located at the cell surface in an inactive state. Integrins are bi-
directional signal receptors and can be activated in two ways: inside-out and outside-in 
stimulation. Both pathways are based on a conformational change in the ectodomain of the 
integrin. The inside-out activation consists of intracellular regulation of the integrin cytoplas-
mic domain by proteins such as kindlin or talin. By the conformational changes of integrins, 
there is an increased binding affinity for extracellular ligands. This activation mechanism con-
trols, among other things, the migration of cells. With the help of outside-in activation, integ-
rins can easily transmit information into the cell. The extracellular binding of a ligand also 
causes conformational changes of integrins and stimulation of intracellular signaling path-
ways. Both signaling pathways, inside-out and outside-in, can regulate each other and also 
lead to CAM-RR (Oxvig et al., 1999; Luo and Springer, 2006; Gahmberg et al., 2009; Shattil 
et al., 2010; Bouvard et al., 2013; Calderwood et al., 2013). 
Intracellular adapter proteins such as paxillin, parvin or talin, members of FAPs com-
plexes, link integrins to the actin cytoskeleton (Fig. 2.2), creating a link between ECM, cell 
membrane, and cytoskeleton. Although integrins do not possess intrinsic kinase activity, they 
can recruit and activate a large spectrum of kinases in the cytoplasm. As a result, important 
cellular processes such as proliferation, apoptosis, differentiation, migration, and cell survival  
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Figure 2.2: Integrins and FAPs contribute to cancer radio- and drug-resistance by mediating cell adhesion 
to the extracellular matrix. Upon cell adhesion to ECM, integrins induce prosurvival signaling cascades and 
thereby contribute to cell adhesion-mediated radiotherapy- and drug-resistance (CAM-RR and CAM-DR). 
 
are regulated by FAPs (Fig. 2.2) (Miyamoto et al., 1995; Yamada and Miyamoto, 1995; 
Hehlgans et al., 2007). 
Besides integrins, there are thousands of proteins which contribute to the adhesome 
(Horton, Byron, Janet a. Askari et al., 2015). Some of them are adaptor proteins, actin regu-
lators, kinases, intermediate filament proteins (IFs), GTPases, and phosphatases. In this 
work, 117 of these FAPs were selected and evaluated in the radiation-induced DSB repair 
and CAM-RR. 
2.3 Intermediate filaments (IFs) 
2.3.1 Cytoskeleton components 
The cytoskeleton is an essential component of the cell; it structures the cell shape, anchors 
main cellular components (such as organelles), and generates roads for transportation 
(Fletcher and Dyche Mullins, n.d.). The cytoskeleton comprises three major constituents: i. 
microfilaments (formed by polymerized actins), ii. microtubules (linear polymers formed by 
alpha and beta tubulins) and iii. intermediate filaments (IFs). Microfilaments are well known 
to be a flexible component of the cell; they are the main component involved in cytokinesis 
and changes in cell morphology. Microtubules have several functions: they form complex 
structures such as in cilia, flagella, and centromeres and they are also, similarly to microfila-
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ments, involved in cell cytokinesis. Moreover, microtubules are the transport roads for vesi-
cles, granules, organelles, and chromosomes via the well-known motor proteins kinesin and 
dynein. IFs, in contrast to the other two cytoskeletal components, are not involved in cell mo-
tility; instead, they mechanically support the plasma membrane of the cells during cell-cell 
interaction or cell-extracellular matrix interaction (Leube et al., 2015; Lowery et al., 2015). In 
fact, IFs have often been identified as active participators of focal adhesion proteins, such as 
vimentin, keratins, vinculin, and synemin. Still, many functions of IFs are unclear, also due to 
the collection of diversities between the IF superfamily members. 
2.3.2 Structure and assembly 
IFs are composed of conserved domains that can be found in almost all members of the su-
perfamily. The major building block of IFs is the α-helical rod domain, which contains four 
different coil structures (Coil 1A, Coil 1B, Coil 2A, and Coil 2B) (Herrmann and Aebi, 2016). 
These structures are firmly held together by linker domains (L1, L12, and L2). The rod do-
main contains high amounts of charged amino acids (AAs), leading to high levels of acidity 
(Herrmann and Aebi, 2016). The head domain balances the acidity from the rod because it is 
highly basic. Depending on the head, rod length, and charge, the assembly of the filaments 
may differ. The third common component of the IFs is the tail domain, which is typically not 
necessary for filament formation, but it contains important information, such as the nuclear 
localization sequence for lamins and regulates the filament width. IFs form heteropolymer 
structures that are quite stable over time, differently from microtubules and microfilaments, 
which are more dynamic. 
2.3.3 Family classification 
IFs are classified into six different families, depending on various factors such as tissue of 
origin and compartmental distribution. The IF protein family shows a high degree of diversity 
due to differences in sequences, sizes, and functionality (Table 2.1). Type I and II are 
keratins, which can be defined as acidic or basic; these two keratins associate together to 
form heterodimers and altogether assemble into keratin filaments (Coulombe et al., 2001; 
Lowery et al., 2015; Anon 2017). Type I and II are composed in total of 33 keratins, 20 being 
epithelial keratins and 13 being trichocytic keratins (components of hair, nails, etc.). Type III 
comprises just four proteins: desmin (mainly identified in sarcomeres), glial fibrillary acidic 
protein (found in astrocytes and glia), peripherin (which arranges in the peripheral neurons), 
with the last protein being vimentin (Coulombe et al., 2001; Lowery et al., 2015; Anon 2017). 
Vimentin is one of the major components of IFs that can be found in many tissues and cells. 
It has important functions such as anchoring of organelles and also in signaling transduction 
from the membrane to the nucleus of the cell. Type IV IFs are found mainly along the axons 
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of neurons, for example neurofilaments form part of this category (Coulombe et al., 2001; 
Lowery et al., 2015; Anon 2017). Other members of this family are: internexin (a component 
of small interneurons and cerebellar granule cells), synemin (found in sarcomere but also in 
neurons), and sincoilin (a muscle-specific intermediate filament). There are still two other 
proteins classified as non-standard subtype IV of the superfamily; these proteins are mainly 
present in differentiated lens fiber cells referred to as filensin and phakinin. Type V IFs are 
found in the nuclear lamina of the cells and are called nuclear lamins (Coulombe et al., 2001; 
Anon 2017). There are two different lamins. A is expressed in differentiated cells. Due to al-
ternative splicing, there are two different isoforms of lamin A: A and C. The second one is 
lamin B, which is present in every cell and also has two important isoforms: B1 and B2. The 
last class of IFs is Type VI, which has only one component termed nestin. This IF is present 
in nerve cells and has a role in the radial growth of axons. 
 
Table 2.1: IF superfamily classification. IFs can be categorized depending on the tissue of origin or intracellular 
localization. To date, there are six different classified groups (adapted from Coulombe et al., 2001). 
Type IF 
MW 
(kDa) 
Tissue Cell location 
I 
Acidic Keratins 
(circa 15 proteins) 
40-68 Epithelia Cytoskeleton, cytosol 
II 
Basic Keratins 
(circa 15 proteins) 
40-69 Epithelia Cytoskeleton, cytosol 
III Desmin 54 Muscle Perinuclear region, cytoskeleton 
 
Glial fibrillary acidic 
protein 
50 
Glial cells and astro-
cytes 
Cytoskeleton, cytosol 
 Peripherin 54 
Peripheral and central 
neurons 
Cell membrane, cytoskeleton, ex-
tracellular exosome 
 
Vimentin 54 
Mesenchyme, all cell 
types 
Cytoskeleton, cytosol 
IV NF-L 62 Mature neurons Cytoskeleton, cytosol 
 
NF-M 60-102 Mature neurons Cytoskeleton 
 
NF-H 106-112 Mature neurons Cytosol 
 
Internexin 55 
Developing central 
nervous system 
Cytoskeleton, nucleus, extracellu-
lar exosome 
 
Synemin 170-210 
Neurons and sarco-
mere 
Cell membrane, cytoplasm, cyto-
skeleton 
 
Syncoilin 55 Sarcomere Perinuclear region 
Non stand-
ard type IV 
Filensin 58-75 Lens fiber cells Cytoskeleton, cytosol 
 
Phakinin 46 Lens fiber cells Cytoskeleton, cytosol 
V Lamin A 65-70 All cell types Nucleus 
 
Lamin B 66 All cell types Nucleus 
 
Lamin C 65-70 All cell types Nucleus 
VI Nestin 177 Nerve cells Cytoskeleton, cytoplasm 
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2.4 Synemin, IV intermediate filament 
2.4.1 Structure 
Synemin was identified as a novel 230 kDa intermediate filament (IF) by Granger and Laz-
arides in 1980. Synemin was co-purificated together with desmin and vimentin filaments from 
smooth muscle; these filaments gave synemin its name — the Greek word synemin means δ 
υν (with) and νη μα (filament). 
Synemin is classified as a IV intermediate filament and it was identified to be genetical-
ly evolved from neuro-filament protein genes (Guérette et al., 2007). In fact, a typical charac-
teristic of these IF, apart from the α-helical domain, is the long tail domain, which encom-
passes 75% of the total size of synemin. 
Synemin cannot homopolymerize and form filaments itself due to its structure, but it 
can copolymerize efficiently with type III IFs. Synemin, as other IFs, contains three main do-
mains: the head (1–10 AAs), the intermediate rod (11–300 AAs), and the long tail (301–1,565 
AAs) as shown in Figure 2.3. The rod itself is formed of three different coiled coils (1A, 1B, 
and 2) separated by short variable linkers. The reason why synemin cannot form filaments 
was well described by Khanamiryan et al. They show that synemin’s inability to form fila-
ments is linked to the short head domain. The IF head is typically formed of positively 
charged residues interacting with the rod domain, which is negatively charged at neutral pH. 
Due to the short length of synemin’s head (just ten AAs), it cannot produce the positive and 
negative balance necessary for dimer-dimer interaction. In the same publication, the authors 
also mention that synemin is missing two conserved motifs in the 2A and 2B coiled coil sub-
domains, both TAAL and TYRKLLEGEE motifs respectively necessary for filament formation 
(Khanamiryan et al., 2008). 
Moreover, synemin C-terminal tail function appears to be fundamental for the formation 
of cross bridges in filaments and binds to many other FA and cytoskeletal components, such 
as α-actinin, dystrophin, talin, vinculin/metavinculin, plectin, utrophin, and zyxin (Geisler and 
Leube, 2016). There are three different synemin isoforms produced by alternative splicing: α, 
β, and L, and they vary mainly in length. For instance, α-synemin is the longest isoform with 
1,565 AAs; β-synemin is slightly shorter and contains 1,251 AAs. The shorter isoform is L-
synemin, which contains 339 AAs and it is composed only of the head and the rod domain 
(Fig. 2.4). Instead, β-synemin is more similar to α-synemin because they only differ in the 
second part of synemin’s tail domain between AAs 1,153 to 1,251 located in the last two ex-
ons in the long C-terminal tail (Fig. 2.4). 
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Figure 2.3: Synemin structure and interaction sites. Synemin comprises three main building blocks: the head 
(AAs 1–10), the coil-linker domain (AAs 11–300), and the tail (AAs 31–1,565). Data taken from UniProt. 
 
 
 
Figure 2.4: Synemin isoforms. Synemin is composed of three isoforms: α, β, and L. A Blast alignment tool 
(https://blast.ncbi.nlm.nih.gov/Blast.cgi) was used to compare the AA sequences of β and L synemin isoforms to 
α-synemin. In the first case (α vs β), the similarity between the two proteins is evident, except for some AAs at the 
distal tail. In the second case (α vs L), it is observable that the L isoform lacks almost the full-length tail. 
 
2.4.2 Physiological role of synemin 
Synemin was originally identified from avian smooth muscles as an intermediate filament due 
to its interactions with desmin and vimentin (B.L Granger and E. Lazarides, 1980). Despite 
having evolved from neurofilament protein genes (Guérette et al., 2007), synemin expression 
is not confined to brain tissue. As mention previously, synemin can be found in myocites but 
also in hepatic stellate, endothelial, and lens cells (Pitre et al., 2012). Depending on the tis-
sue of origin, synemin seems to have different functions and interaction partners. For in-
stance, synemin is involved in the assembly of focal adhesions together with des-
min/vimentin, forming hetero-polymeric filaments in muscle cells (Jing et al., 2005; Sun et al., 
2010). Typically, synemin localizes in actin-rich regions such as lamellipodia (Bellin et al., 
1999). Synemin is considered to be a kinase anchoring protein (AKAP) with scaffold func-
tions regulating the anchoring ability of protein kinase A (PKA) in heart tissue (Russell et al., 
2006) through the interaction with the PKA regulatory subunit type II (RII) binding site. PKA is 
a family of enzymes which function as kinases regulated by cyclic AMP levels. This kinase is 
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mainly involved in cell metabolism, and deregulation may lead to muscular atrophy. In line 
with these observations, the Bloch group has determined that absence of synemin causes 
structural and functional abnormalities in the heart (García-Pelagio et al., 2018). That group 
reported that synemin silencing leads to left ventricular systolic dysfunction and hypertrophy 
accompanied by dilatation. Synemin deficient cardio-myocytes showed alterations in calcium 
handling and in several signaling proteins (PKA-RII, ERK, and p70S6K) which are critical to 
cardiomyocyte function (García-Pelagio et al., 2018). Furthermore, the Bloch team has 
demonstrated that synemin silencing not only affects cardiac muscle but also skeletal muscle 
functionality, leading to a decreased bone density also known as osteopenia (García-Pelagio 
et al., 2019). Since the discovery of synemin, few groups have been working in order to un-
derstand synemin molecular mechanisms and its physiological role. Still, synemin function 
has not been clearly understood and may differ from tissue to tissue. 
2.4.3 Synemin in cancer 
The molecular function of synemin in cancer can differ depending on the tumor entity. In gli-
oma cells, synemin is overexpressed and is associated with enhanced cancer cell prolifera-
tion and survival (Pitre et al., 2012). Likewise, synemin promotes proliferation and motility of 
astrocytoma cells (Pan et al., 2008; Skalli et al., 2013). Furthermore, synemin has been iden-
tified in several sarcomas, including leiomyosarcomas and gastrointestinal stromal cell tu-
mors (GIST). Synemin was described as a good diagnostic marker for GIST because it was 
found in proto-oncogene tyrosine kinase receptor CD117+ positive cells (Criswell et al., 2018; 
Criswell et al., 2019). In the present study, synemin expression was observed in all applied 
head and neck squamous cell carcinoma (HNSCC) cell lines, similar to gliomas and astrocy-
tomas. Interestingly, in many squamous cell carcinomas, such as lung (LUSC), cervical 
(CESC), and HNSCC, the DNA copy number of the SYNM gene was amplified (Network, 
2015). In contrast, a study in breast cancer cells demonstrated that the SYNM gene can be 
hypermethylated, leading to down-regulation of synemin expression (Noetzel et al., 2010). 
When this down-regulation occurs, the breast cancer cells acquire a more migrating pheno-
type, leading to an increased level of lymph node metastasis. 
Skalli’s group reported that the malignant role of synemin in glioblastoma is indirectly 
associated with the regulation of Akt activity. Synemin was characterized as a regulator of 
protein phosphatase 2 A (PP2A) (Pitre et al., 2012). As a result of synemin depletion, an in-
creased PP2A phosphatase activity down-regulated Akt activity, attenuating the pro-survival 
mechanism of glioma cells. Besides the direct interaction with Akt, PP2A modulates the DNA 
DSB repair mechanism by dephosphorylating γH2AX after DNA repair has been completed. 
The authors reported the direct interaction between synemin and PP2A located solely inside 
the nucleus, but the authors did not further investigate the underlying mechanisms. 
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2.5 Head and Neck squamous cell carcinomas (HNSSC) 
Head and neck cancers (HNCs) encompass a heterogeneous group of malignant tumors that 
arise in the upper oral cavity including the pharynx (nasopharynx, oropharynx and hypophar-
ynx), larynx, and oral/nasal cavity. Other common areas where this tumor can develop are 
the tongue, salivary glands, and paranasal sinuses. Approximately 90% of HNCs are squa-
mous cell carcinomas (HNSCCs). Worldwide, more than 300,000 new cases of HNSCC and 
about 150,000 deaths per year were estimated (Ferlay et al., 2015). In Germany, HNCs more 
often affect the male population and around 8% of men die from it every year (Fig. 2.5) (Koch 
Institute and Centre for Cancer Registry Data, 2009). Although HNSCC represents only a 
small proportion of the overall cancer incidence, the prognosis of patients with HNSCC re-
mains poor, with a 5-year overall survival rate of 50%. 
 
Figure 2.5: Percentage of the most frequent tumor sites when cancer was the leading cause of death in 
Germany (2014). Estimated percentage of tumor incidence and tumor as cause of death in different areas of the 
body in men and women living in Germany. Different components of HNCs tumors are shown in bold: Esophagus, 
oral cavity, pharynx, and larynx (Modified from Cancer in Germany, 2013/2014).  
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2.5.1 Common therapeutical approaches 
Radiotherapy remains an indispensable element for the curative care of HNSCC. Treatment 
choice for early stage HNSCC is either surgery or radiotherapy as a single modality, whereas 
multimodal treatment is important for treating patients with locally advanced HNSCC in stag-
es T3 or T4 (Colevas et al., 2018). Recent developments of curative treatment of HNSCC 
include: a) optimization of fractionation schedules, b) the use of high-precision radiotherapy 
modules (i.e., proton therapy and intensity-modulated radiation therapy), and c) implementa-
tion of chemotherapeutics or immunotherapeutics in treatment plans (Haddad and Shin, 
2008; Santuray et al., 2018). Commonly used drugs are for example cisplatin, bleomycin, 
cetuximab, docetaxel, hydroxyurea, and many others depending on the tumor characteristics 
and stages (https://www.cancer.gov/about-cancer/treatment/drugs/head-neck). 
2.5.2 Risk factors 
The most common risk factors for HNSCC development are excessive and long-term con-
sumption of alcohol and tobacco in the older population (Kuriakose et al., 1992; Llewellyn et 
al., 2001; Schmidt et al., 2015). However, recent studies showed an increasing number of 
young subjects with oral squamous cell carcinoma (SCC), despite low consumption of these 
substances (Kuriakose et al., 1992; Schmidt et al., 2015). In these cases, the pathogenesis 
of HNSCC in young people is attributed to genetic and other behavioral factors (Schmidt et 
al., 2015). Genetic factors include genetic predisposition to cancer (i.e. factors related to 
DNA instability such as DNA ploidy or chromosomal fragility and rearrangement). Genetic 
instability can lead to gain and loss of chromosome regions, resulting in mutations that will 
affect cell cycle progression checkpoints and activation of proto-oncogenes (Kuriakose et al., 
1992; Kaminagakura et al., 2011). There is also a so-called familial risk, which involves an 
increased probability of developing cancer if a first-degree family member has suffered from 
HNSCC (Schmidt et al., 2015). 
Other risk factors are immuno-deficiencies, such as chronic syndromes (Bloom syn-
drome, Wiskott-Aldrich syndrome) or anemia (Patterson Kelly/ Plummer Vinson syndrome, 
Fanconi anemia) (Toner and O’Regan, 2009; Schmidt et al., 2015). In Fanconi anemia for 
example, the DNA repair machinery is partly impaired, leading to an increased probability of 
developing cancer. In fact, a subject suffering from Fanconi anemia has a 40% risk to devel-
op HNC (Toner and O’Regan, 2009; Schmidt et al., 2015).  
Last but not least viral infections, such as the human papillomavirus (HPV), are a 
common risk factor. There are two different subtypes of HPV viruses depending on low and 
high risk of leading to cancer development (Chaturvedi and Chocolatewala, 2009). For ex-
ample, HPV-16 and HPV-18 are high-risk viruses. Viral DNA produces onco-proteins, known 
as E6 and E7, affecting the infected cell’s normal behavior (Schmidt et al., 2015), leading to 
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genomic instability and cell immortalization. However, it is well known that HPV-positive head 
and neck tumors are associated with a more favorable outcome (Ganci et al., 2015) and bet-
ter response to standard therapy. 
2.6 Effects of ionizing radiation on cellular level 
Radiation therapy is a standard treatment for cancer, and it is typically applied in combination 
with chemotherapy and/or surgical removal of the tumor bulk. By its genotoxic property, radi-
ation damages the DNA to the degree that cancer cell survival and proliferation is reduced. 
For this reason, approximately 50–60% of all cancers are treated with irradiation (Koch 
Institute and Centre for Cancer Registry Data, 2009; Begg et al., 2011; Moding et al., 2013). 
Irradiation can be classified into two groups: the first one is particulate irradiation (electrons, 
neutrons, α-particles, protons, or heavy ions), and the second one is electromagnetic or pho-
ton irradiation (X- and γ-rays). X-rays are prevalent for cancer therapy treatment (Hall and 
Giaccia, 2012). 
Ionizing radiation is defined as radiation with sufficient energy to eject an electron out 
of the atom orbital of a target molecule such as water or intracellular macromolecules. Radia-
tion can be classified into a) directly ionizing and b) indirectly ionizing radiation. In contrast to 
direct ionization where the energy is directly deposited on target molecules, indirect ioniza-
tion does not directly cause damage to target molecules but rather ionizes other molecules 
(e.g. water or intracellular macromolecules) which in turn damage/ionize target molecules. 
An example of frequent ionized molecules by X-ray are water molecules in solution (radioly-
sis of water (Breen and Murphy, 1995)). 
Upon ionization of water molecules, an aqueous electron (eaq
- ) and oxygen (1+) dihy-
dride (H2O+) (Eq. 1) are generated. The oxygen (1+)dihydride then reacts with a nearby wa-
ter molecule (Eq. 2) forming a hydronium ion (H3O+) and a hydroxyl radical (⦁OH), both of 
which can cause further damage to surrounding molecules. 
 
 H2O 
hν
→  H2O
++ eaq
-  (1) 
 H2O
++ H2O → H3O
+ + ⦁OH (2) 
   
Because cells are composed of 80% water, it is likely that most damage occurs due to 
indirect ionization upon irradiation of biological materials. 
During ionizing radiation, multiple reactive oxygen species are generated. These spe-
cies react with several biological elements such as proteins (Kumta and Tappel, 1961), 
Background 
15 
membrane lipids (Konings, 1987), and DNA molecules (Schulte-Frohlinde and Bothe, 1991), 
generating damage and disrupting their functions. 
The major target of ionizing radiation is DNA. Inducing damage to DNA can lead to cell 
death, mutagenesis, and carcinogenesis. In figure 2.6, the direct and indirect damage on 
DNA induced by ionizing radiation is illustrated. The energy generated from X-ray is typically 
distributed along the tracks of the charged particles, also defined as spurs. Interestingly, 
spurs composed of three ion pairs have a diameter of 4 nm, which is twice the size of the 
DNA helix size (2 nm), implying that if the spurs overlap the DNA, multiple radical attacks can 
occur and damage can be induced (Hall and Giaccia, 2012). 
Irradiation induces different forms of damage in DNA, such as: change, modification, or 
loss of bases; single strand breaks (SSBs) and double strand breaks (DSBs). A single dose 
of 1 Gy irradiation can induce up to 1,000 SSBs and 20–40 DSBs. Additionally, SSBs on 
both strands in close proximity can lead to the formation of a DSB. It is widely recognized 
that the most lethal form of damage for cells relates to DSBs. In fact, if left unrepaired or in-
correctly repaired, DSBs can lead to abnormal chromosome rearrangements (translocations, 
deletions) and cell death (Kinner et al., 2008; Galluzzi et al., 2012). Chromosome rear-
rangements can lead to cell transformation or increase the risk of cancer development (Hall 
and Giaccia, 2012). 
To overcome their fate after DNA damage induction, cells have developed defensive 
mechanisms, such as DNA damage response and repair. After correct repair, cells regain 
their functionality and the ability to reproduce. 
 
Figure 2.6: Ionizing radiation induces damage to macromolecules. Direct damage to DNA and other macro-
molecules is induced by ionization of the molecules and disruption of their chemical bonds. Damage can be indi-
rectly inflicted by ionization of surrounding water molecules, producing free radicals, which in turn cause damage 
to the biomolecules. Source: Hall and Giaccia, 2012.  
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2.7 DNA damage response 
DNA damage is not only caused by irradiation. In fact, circa 70,000 endogenous lesions oc-
cur daily under natural circumstances. Twenty of these lesions are DNA DSBs, serving as a 
source of spontaneous mutations (Tubbs and Nussenzweig, 2017). To repair DNA damage, 
eukaryotic cells have developed a signaling network termed DNA damage response (DDR), 
which can trigger cell cycle arrest, DNA repair, and apoptosis (Ciccia and Elledge, 2010). 
After the activation of the DDR, the main DNA repair machinery is activated consisting of: 
non-homologous end joining (NHEJ), homologous recombination, (HR) and in some cases 
alternative end joining (alt-EJ) (Fig. 2.7) (Willers et al., 2004; Chang et al., 2017). 
Commonly, the MRN complex consisting of meiotic recombination 11 (Mre11), Rad50 
and Nijmegen breakage syndrome protein 1 (Nbs1) recognizes the DNA DSB. After recogni-
tion, the Mre11 mediates DNA end resection due to its endonuclease and exonuclease ac-
tivities (Hopfner et al., 2001). Rad50 protein is instead responsible for DNA binding and pos-
sesses ATPase and adenylate activity (Paull and Gellert, 1999). Nbs1 is simply responsible 
for nuclear localization of the MRN complex (Williams et al., 2010). Once the MRN complex 
is located at the damage site, it facilitates the recruitment of three main kinases: ataxia telan-
giectasia mutated (ATM), ataxia telangiectasia and Rad3 related (ATR), and DNA-dependent 
protein kinase catalytic subunit (DNA-PKcs) (Bristow and Hill, 2008). 
ATM, a serine/threonine kinase, is probably the main player in damage recognition 
(Roos and Kaina, 2013). ATM is named after the human autosomal recessive disorder ataxia 
telangiectasia mutated caused by mutations in the ATM gene (Savitsky et al., 1995) and is a 
key protein of the phosphatidylinositol 3-kinase-related kinase pathway (PIKK) (Uziel et al., 
2003). ATM phosphorylates several DDR proteins such as H2AX, p53, checkpoint kinase 2 
(Chk2), Nbs1, breast cancer tumor suppressor protein-1 (BRCA1) and structural mainte-
nance of chromosomes 1 (SMC1) after its own activation (Fig. 2.8). 
After damage recognition and recruitment of the MRN complex, histone H2AX phos-
phorylation results in the formation of γH2AX in the DSB vicinity in less than ten minutes after 
the damage induction. Besides the MRN complex, the activation of ATM is also mediated by 
a feedback loop, regulated by γH2AX and 53BP1 (p53-binding protein 1) loci formation (Uziel 
et al., 2003). The immunological detection of 53BP1 and γH2AX is used for visualization and 
quantification of radiation-induced DSBs (Löbrich et al., 2010). The DSBs are described as 
foci which disappear after DNA damage repair, while unrepaired foci remain stable and are 
manifested as residual foci at 24 h post irradiation (Banáth et al., 2004). 
DNA damage sensing factors and DNA damage repair proteins involved in HR and 
NHEJ are subsequently recruited (Bristow and Hill, 2008). The competition of NHEJ and HR 
as DNA DSB repair pathways is partly controlled by 53BP1 and BRCA1 (Fig. 2.7). 
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Figure 2.7: DNA repair mechanism distributed in the cell cycle. NHEJ is active during the entire cell cycle and 
is characterized by low resection of the damaged DNA. Instead, HR and Alt-EJ are mainly functional during late S 
and G2 phase, and DNA resection is necessary for these machineries. 
 
53BP1, another ATM kinase substrate, dismisses the end resection mediated by MRN com-
plex to favor NHEJ. Conversely, BRCA1, a tumor suppressor gene, promotes end resection 
and removes 53BP1 from DSB to initiate HR (Daley and Sung, 2014). A defect in one of the 
DNA DSB recognition and repair pathways is strongly associated with extensive genomic 
instability and high radiosensitivity (Pollard and Gatti, 2009). 
2.8 DNA double strand break repair mechanisms 
As described previously, eukaryotic cells have developed two main mechanisms for repair of 
DSB: HR and NHEJ. However, Alt-EJ also plays an important role in cancer treatment. In 
addition to 53BP1 and BRCA1, the decision of which mechanism will be implemented for the 
repair of DNA damage depends on the cell cycle phase (Fig. 2.7 and Fig. 2.8). NHEJ mainly 
takes place during G1- and early S phase, but it is active during the entire cell cycle. Be-
cause NHEJ does not require a template for DSB repair, this mechanism of damage repair 
can be error prone (Goodarzi and Jeggo, 2013). Instead, the HR operates only in dividing 
cells during late S- and G2-phase. HR is a high-fidelity repair mechanism due to the fact that 
it uses an intact homologue sister chromatid as a template for correct DSB repair (Iyama and 
Wilson, 2013). In cancer, when HR is not working appropriately, end resection that generates 
3’ single strands still occurs during G2/S phase and in this case, Alt-EJ repairs the DNA 
DSBs. Similarly to HR, this mechanism takes place during late S- and G2-phase but unlike 
HR, Alt-EJ does not use the sister chromatid as a template, leading to erroneous repair in-
troducing mutations. Furthermore, this mechanism is commonly highly slow (Ceccaldi et al., 
2016).  
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Figure 2.8: DSB DNA repair mechanisms. The main DSB DNA repair mechanisms are NHEJ, HR, and Alt-EJ. 
NHEJ is highly dependent on 53BP1 and the Ku complex which will recruit DNA-PKcs kinase. Instead, HR and 
Alt-EJ depend on CtIP and the MRN complex which will lead to end resection and the formation of a single 
stranded DNA, which will be repaired using the sister chromatid in the case of HR or by micro-homology in the 
case of Alt-EJ (Ceccaldi et al., 2016). 
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2.8.1 Non-homologous end joining (NHEJ) 
The NHEJ is based on the direct ligation of two ends and is the major repair pathway in 
higher eukaryotes (Lieber, 2010). NHEJ is initiated by the recognition of the DSB and binding 
of the Ku heterodimer complex (Ku70-Ku80) to both ends of the break, thereby preventing 
extensive DNA end resection (Fig. 2.8). Subsequently, the Ku heterodimer recruits 
DNA-PKcs to DSB sites forming the Ku/DNA-PKcs complex. The complex formation stimu-
lates the kinase activity of DNA-PKcs, stabilizing and aligning the DNA ends (Rathmell and 
Chu, 1994; Mladenov et al., 2016). To achieve end-processing of the DNA ends and to re-
move non-ligable parts, the endonuclease Artemis is phosphorylated and recruited to DSB 
sites by DNA-PKcs. Artemis then recruits polymerase β (Polβ) to modify the DNA ends and 
produce appropriate strands for ligation (Löbrich and Jeggo, 2005). Ligation is necessary to 
terminate the repair; during this final step of NHEJ, Ligase IV (LIG4) together with X-ray re-
pair cross complementing 4 (XRCC4), XRCC4-like factor (XLF), and Polynucleotide kinase 
3'-phosphatase (PNK) are recruited and collectively join the processed DNA strands (Koch et 
al., 2004). 
As previously mentioned, NHEJ is considered to be an error-prone mechanism, in 
which two ends of a DSB break are rejoined without the use of homology. This process is 
fast but less accurate, thereby causing small deletions or insertions. Despite the enhanced 
risk of error, gene coding and regulatory regions account for only a minimal fraction of the 
total genome (ENCODE Project Consortium, 2012), minimizing the probability of damage 
occurring at protein coding regions. Thereby, the consequence of minor deletions or inser-
tions caused by NHEJ are minimal or non-essential (Joiner and van der Kogel, 2009). More-
over, NHEJ is active throughout the entire cell cycle, providing a flexible repair mechanism 
and increasing the survival chance of damaged cells (Mladenov et al., 2016). 
2.8.2 Homologous recombination (HR) 
In contrast to NHEJ, the HR mechanism requires an intact sister chromatid as a template for 
correct repair. Firstly, ATM phosphorylates BRCA1, which is subsequently recruited to DNA 
DSB ends (Fig. 2.8). The MRN complex associates with the C-terminal binding protein-
interacting protein (CtIP). CtIP initiates 5’-3’ resection and generates 3’ single-strand over-
hangs (Sartori et al., 2007), which are immediately coated by replication protein A (RPA) to 
stabilize the exposed ssDNA. RAD52 and BRCA2 promote the replacement of RPA by 
RAD51, resulting in nucleoprotein filaments. RAD52 is attracted to RAD51-coated nucleopro-
tein filaments to prevent exonucleolytic degradation. RAD51 supports the invasion of the 3’ 
overhang of the intact homologous DNA region (Kass and Jasin, 2010), leading to the for-
mation of a holiday junction. Finally, supported by RAD54 protein, the DNA polymerase ex-
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tends the missing parts and the holiday junction is resolved with the support of ligases con-
necting the remaining DNA breaks, thereby closing the gap (Goodarzi and Jeggo, 2013). 
HR is a slower process compared to NHEJ and requires circa 6 h to conclude the 
damage. This time is therefore important because it provides cells with an accurate DSB re-
pair mechanism. Germline or somatic mutations of HR repair genes are strongly associated 
with hereditary diseases and tumorigenesis. For instance, BRCA1/2-mutated genes likely 
dictate the risk of breast cancer, prostate cancer, and ovarian cancer development (Levy-
Lahad and Friedman, 2007). Moreover, patients with hereditary diseases such as Fanconi 
anemia, Bloom disease, and Werner disease, all of which are caused by defects in HR 
genes, are reported to have an extremely high radiation sensitivity (Pollard and Gatti, 2009; 
Krejci et al., 2012). 
2.8.3 Alternative end-joining (Alt-EJ) 
The term alternative end-joining (alt-EJ) is derived from NHEJ because it was believed to be 
activated during a deficiency of NHEJ. However, it is still an open question whether alt-EJ is 
a stand-alone pathway or it is only involved in several processes relying on NHEJ, such as 
replication and DSB repair (Chang et al., 2017). Alt-EJ is well known for using micro-
homology sequences between the two DNA single strands to perform ligation and repair. Alt-
EJ is highly dependent on four components: poly(ADP-ribose) polymerase I (PARP1), Pol θ, 
CtIP, and MRN complex. At the DNA DSB site, PARP1 is recruited and competes with the 
Ku complex for access to the damage (Chang et al., 2017). At the same time, PARP1 may 
be involved in the recruitment of MRN complex to the damage and, in the absence of Ku sta-
bilizing the strand, Mre11 can start with strand processing (Fig. 2.8). When the processed 
ends present more than 2 bp of homology, Pol θ becomes activated and using the annealed 
partner template, it inserts templated insertions, leading to erroneous repair. The Alt-EJ re-
pair mechanism is slower and more mutagenic compared to NHEJ and HR (Ray Chaudhuri 
and Nussenzweig, 2017). 
In the clinic, PARP1 inhibitors are widely used for patients whose tumors present with 
BRCA1 deficiency. In fact, during the S/G2 phase, HR is active and end resection is more 
likely to occur. However, in BRCA1-deficient cells, HR cannot take place and as a surrogate, 
alt-EJ repairs the damage (Ray Chaudhuri and Nussenzweig, 2017). 
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3 Hypothesis and Aims 
Various factors such as the microenvironment of tumors, gene mutations and epigenetic 
changes have a decisive influence on the success of cancer therapy and can lead to the de-
velopment of therapy resistance. As a further source of therapy resistance, tumor cells attach 
to neighboring cells and to ECM, events shown as key drivers of resistance. While adhesion 
to neighboring cells and the extracellular matrix (ECM), including focal adhesion formation, is 
not limited to the large family of integrin receptors, inevitable proteins of these processes are 
FAPs. Cell adhesion molecules together with FAPs facilitate the linkage between ECM, intra-
cellular cytoskeleton and nuclear membrane as well as other mechanisms such as cell-
matrix communication. 
Despite of all our current knowledge about pro-survival signaling via focal adhesions, it 
is unclear whether and how FAPs can influence the survival of cells through the regulation of 
radiation-induced DNA damage repair. Consequently, we hypothesized in the present study 
that FAPs fundamentally impact on HNSCC cell survival upon radiochemotherapy through 
the regulation of DNA repair mechanisms. 
The aim of this study was to identify the mechanisms of radiation-induced DNA double 
strand break (DSB) repair as a function of specific FAPs in HNSCC cell lines. To systemati-
cally search for novel FAP candidates driving the cancer therapy resistome by linking extra-
cellular cues to intracellular DNA repair decisions, a high-throughput RNA interference 
screen (3D-HTPS-RNAi-S) combined with X-ray irradiation of HNSCC cultures grown in 3D 
ECM laminin-rich ECM was established. This 3D ECM system has been previously shown to 
resemble in vivo growth conditions. After the screen, synemin resulted as one of the key tar-
gets controlling radiosensitivity and DNA damage repair. Synemin knockdown was used for 
silencing the protein and DSB were induced by X-rays. In order to investigate an association 
between synemin and DSB repair and to identify the molecular interaction, residual DSB 
rate, clonogenic survival, NHEJ activity, protein expression, phosphorylation and localization, 
kinase activity, protein-protein interactions and complex formation were determined. Since 
the connection between ECM, FAPs, actin cytoskeleton and nucleus plays an important role 
in nuclear organization and influences the DNA repair machinery, the role of synemin as 
linker protein was analyzed. 
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The results of this work show how synemin regulates the repair of radiation-induced 
DSB and, thus, contributes to our molecular understanding of synemin-mediated survival 
signaling. Further, these findings add important facets to our knowledge about cytoarchitec-
tural elements such as intermediate filaments and their function as key co-regulators of nu-
clear DNA repair. 
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4 Materials and Methods 
4.1 Materials 
4.1.1 Devices 
Table 4.1. Devices used for the biochemical, molecular-biological and cell culture experiments. 
Device Type Company 
Autoclave V-65 Systec, Wettenberg, D 
Barometer  Conrad Electronics, Hirschau, D 
Binocular, incl. light source Stemi2000 Carl Zeiss, Jena, D 
Bio Imaging System  Genius Syngene Syngene, Cambridge, GB 
Centrifuge 
5415R (for 15, 50 ml reaction 
tubes) 
Eppendorf, Hamburg, D 
Centrifuge 
S415R (for 1,5 ml Safe-Lock 
reaction tubes) 
Eppendorf, Hamburg, D 
Dosimeter PTW Unidos PTW, Freiburg, D 
Cytometers 
FACs CantoTM II 
FACs Celesta 
BD, Heidelberg, D 
Film welding tool Dual Electronic Jencons-PLS, London, GB 
Freezer, -20 °C KX1011 Liebherr, Ochsenhausen, D 
Freezer, -80/ -150 °C  Heraeus Holding GmbH, Hanau, D 
Fridge  Liebherr, Ochsenhausen, D 
Gel electrophoresis-System for 
LDH-Analysis 
Paragon® Electrophoresis 
System 
Beckmann Instruments, Fullerton, 
USA 
Hand drill Xenox Nail 35k Xenox, Föhren, D 
Ice machine AT-10 Scotsman, London, GB 
Incubator bacteria  Memmert, Schwabach, D 
Incubator cell culture HeraCel Heraeus Holding GmbH, Hanau, D 
Incubator for liquids  Heraeus Holding GmbH, Hanau, D 
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Device Type Company 
Inverted Microscope Axiovert 25 Carl Zeiss, Jena, D 
Laser Scanning Microscope 
(LSM) 
Axiovert 200M,  
LSM 510 Meta 
Carl Zeiss, Jena, D 
Microwave  
Sharp Electronics (Europe) GmbH, 
Hamburg, D 
PCR cycler Mastercycler epgradient Eppendorf, Hamburg, D 
pH-meter ph Level 1 inoLab, Weilheim, D 
Power Supply EPS601 Amersham, Freiburg, D 
Precision scale LE244S-0CE Sartorius, Göttingen, D 
Rotary shaker CERTOMAT®IS 
B. Braun Melsungen AG, Melsun-
gen, D 
Scale BL 1500S Sartorius, Göttingen, D 
Semi Dry Blotter TE77 Amersham, Freiburg, D 
Shaker Polymax 1040, 2040 Heidolph, Schwabach, D 
Shaker KS260 basic IKA, Staufen, D 
Spectrophotometer Nano-Drop-1000 
PEQLAB Biotechnologie GmbH, 
Erlangen, D 
Stirrer, incl. heating MR3001 Heidolph, Schwabach, D 
Sterile work bench Clean Air  Heraeus Holding GmbH, Hanau, D 
Stereotactic instrument 
Just for Mouse Stereotaxic 
Instrument STO-51730 
Stoelting Co., Wood Dale, IL 
Tecan Microplate-Reader Genios Pro Tecan, Crailsheim, D 
Thermomixer comfort 1,5 ml Eppendorf, Hamburg, D 
Vacuum pump Vacusafe comfort 
VacuSafe IBS Integra Bioscience, 
Chur, CH 
Vertical gel-electrophoresis 
chamber incl. accessory parts 
SE250 Hoefer, San Francisco, USA 
Vortex mixer Reax control VWR, Darmstadt, D 
Water bath SW22 
Julabo Labortechnik GmbH, Seel-
bach, D 
X-ray device Y.TU320 
Yxlon International GmbH, Ham-
burg, D 
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4.1.2 Further materials 
Table 4.2. Materials used for the biochemical, molecular-biological and cell culture experiments. 
Material Company 
Cell culture flasks; T-25, T-75, T-175 cm2 Corning Life Science, Wiesbaden, D 
Cell culture plates, 96-Well, flat bottom Corning Life Science, Wiesbaden, D 
Cell culture plates; 6-, 12-, 24-Well BD, Heidelberg, D 
Cell culture plates; 60 mm, 100 mm BD, Heidelberg, D 
Cell scraper; 40 cm BD, Heidelberg, D 
Centrifuge tubes; 15 ml, 50 ml Greiner Bio-one GmbH, Frickenhausen, D 
Coverslips, 12 mm, round Glaswarenfabrik Karl Hecht KG, Sondheim, D 
Cryo vials Biochrom, Berlin, D 
Glass pasteurpipets Brand GmbH u. Co. KG, Wertheim, D 
Hamilton-Syringe, 100 µl Hamilton Bonaduz AG, Bonaduz, CH 
Hamilton-Syringe, 10 µl Hamilton Bonaduz AG, Bonaduz, CH 
HyperTM ECL-films Amersham, Freiburg, D 
Instrument case Roth, Karlsruhe, D 
Insulin syringe, 0,3 mm x 12 mm Braun, Melsungen, D 
Laboratory bottles Schott AG, Mainz, D 
Nitrocellulose membrane Protran; 0,2 µm Schleicher & Schuell, Dassel, D 
Microscopy slides, Superfrost Roth, Karlsruhe, D 
Pipette tips with filter, sterile; 10-1000 µl Sarstedt, D 
Pipettes; 1, 5, 10, 25 ml BD, Heidelberg, D 
Pipette controller, accu jet pro Brand, Herrenberg, D 
Protein A/G beads, 50% slurry Alpha Diagnostics, Paramus, USA 
Reaction tube, Safe Lock; 1,5 ml, 2 ml Eppendorf, Hamburg, D 
Reaction tube rack Rotilab, Roth, Karlsruhe, D 
Whatman filterpaper; 3 mm Bender-Hobein, Zürich, CH 
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4.1.3 esiRNA and siRNA 
Table 4.3. Endoribonuclease-prepared small interfering (esi)RNAs or small interfering (si)RNAs used to silence 
the indicated genes. Corresponding sequences are shown. 
RNAi Sequence (Sense) Company 
esiRLUC 
5’-
ATTTATTAATTATTATGATCAGAAAAACATGCAGA
AAATGCTGTTATTTTTTTAC-3’ 
Eupheria Biotech 
esiSYNM 
5’-
AAACAGACCAGAAACCATCCGAACAAA-
GCCAGAA-GAGAAAATGTTCGATTCTAA-3’ 
Eupheria Biotech 
siCTRL#1 5’- AAAACAGUUGCGCAGCCUGAAtt-3’ 
MWG Eurofins, Ebersberg, 
D 
siSYNM#1 5’- GCCGAUUAGUCUAGAAGUAtt -3’ 
MWG Eurofins, Ebersberg, 
D 
siSYNM#2 5‘-CGGUGAAUUUCAUGCCGAAtt-3‘ 
MWG Eurofins, Ebersberg, 
D 
siSYNM#3  5‘-GCCUUACCAUGCAUUUCCGtt-3‘ 
MWG Eurofins, Ebersberg, 
D 
sic-Abl 5‘-GGCCAUCAACAAACUGGAGtt-3‘ 
MWG Eurofins, Ebersberg, 
D 
siDNA-PKcs 5‘-GGCAAUUCGUCCUCAGAUUtt-3‘ 
MWG Eurofins, Ebersberg, 
D 
4.1.4 Inhibitors and chemotherapeutic agents 
Table 4.4. Inhibitors and chemotherapeutics used for in vitro experiments.  
Inhibitor Target Company 
Cisplatin Teva® DNA intercalator Teva GmbH 
Imatinib c-Abl Selleckchem 
NU7026 DNA-PKcs Selleckchem 
KU55933 ATM Calbiochem 
4.1.5 Plasmids 
Applied plasmids are described in Table 4.5. The mCherry-Synemin plasmid expressing a 
red fluorescent synemin fusion protein was a gift from R. J. Bloch (University of Maryland, 
USA). The plasmid was further validated by sequencing and used for the generation of dif-
ferent synemin constructs (mCherry-Synemin ΔLinker-Tail, mCherry-Synemin ΔHead-Linker, 
mCherry-Synemin-ΔHead-Linker-Tail1, mCherry-Synemin ΔHead-Linker-Tail2, mCherry-
Synemin ΔHead-Linker-S1114A and mCherry-Synemin ΔHead-Linker-S1159A) by PCR as 
described in 4.2.18.1 Corresponding empty vectors were used as control. Vector pEGFP-N1 
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and ISCEI endonuclease were gifts from K. Borgmann (Medical Center Hamburg-Eppendorf, 
Germany) (Pierce et al., 1999; Krajewska et al., 2013). 
 
Table 4.5. Plasmids used for cloning, overexpression, flow cytometry, fluorescence microscopy and immunopre-
cipitation. 
Plasmid Resistance Specification Supplier 
pmCherry-C1 KanR, NeoR 
Expression vector for generation of 
fusion proteins; high copy number; 
CMV-Promotor 
Clontech 
pmCherry-Synemin KanR, NeoR 
mCherry, high copy number; CMV-
Promotor; b-Expression vector ex-
pressing αSynemin isoform 
R. J. Bloch 
(University of 
Maryland, USA) 
mCherry-Synemin 
ΔLinker-Tail 
KanR, NeoR 
mCherry, high copy number; CMV-
Promotor; b-Expression vector ex-
pressing Synemin Head domain 
N. Cordes (TU 
Dresden, Ger-
many) 
mCherry-Synemin 
ΔHead-Linker 
KanR, NeoR 
mCherry, high copy number; CMV-
Promotor; b-Expression vector ex-
pressing Synemin Tail domain 
N. Cordes (TU 
Dresden, Ger-
many) 
mCherry-Synemin 
ΔHead-Linker-Tail2 
KanR, NeoR 
mCherry, high copy number; CMV-
Promotor; b-Expression vector ex-
pressing Synemin first part of the Tail 
domain (from 301 to 961 AAs) 
N. Cordes (TU 
Dresden, Ger-
many) 
mCherry-Synemin 
ΔHead-Linker-Tail1 
KanR, NeoR 
mCherry, high copy number; CMV-
Promotor; b-Expression vector ex-
pressing Synemin second part of the 
Tail domain (from 962 to 1565 AAs) 
N. Cordes (TU 
Dresden, Ger-
many) 
mCherry-Synemin 
ΔHead-Linker-S1114 
KanR, NeoR 
mCherry, high copy number; CMV-
Promotor; b-Expression vector ex-
pressing Synemin Tail domain with 
S1114A AA. mutated 
N. Cordes (TU 
Dresden, Ger-
many) 
mCherry-Synemin 
ΔHead-Linker-S1159 
KanR, NeoR 
mCherry, high copy number; CMV-
Promotor; b-Expression vector ex-
pressing Synemin Tail domain with 
S1159G AA. mutated 
N. Cordes (TU 
Dresden, Ger-
many) 
pcDNA3-Myc-NLS-ISceI AmpR, NeoR 
Expression vector expressing a nu-
clear localization sequence b-
Endonuclease for DSB induction; 
high copy number; CMV-Promotor 
K. Borgmann 
(Medical Center 
Hamburg-
Eppendorf, 
Germany). 
pEGFP-N1 KanR, NeoR 
Expression vector for generation of 
fusion proteins; high copy number; 
CMV-Promotor 
Invitrogen 
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4.1.6 Primers 
Table 4.6. Primers used for the amplification and flanking of SYNM (synemin gene) with the indicated restriction 
sites. Respective sequences are shown. 
Primer Sequence (Sense) Company 
Synemin ΔLinker-Tail-F 
5’-
AGCTTcgATGCTGTCCTGGCGGCTGCAGAC-
GGGCCCCG-3’ 
MWG Eurofins, 
Ebersberg, D 
Synemin ΔLinker-Tail-R 
5’-
AgcTACGACAGGACCGCCGAC-
GTCTGCCCGGGGCCTAG-3’ 
MWG Eurofins, 
Ebersberg, D 
Synemin ΔHead-Linker-F 
5’-cccAAGCTTcg-
GTGAAGACCGGCCTCAGTCTGG-3’ 
MWG Eurofins, 
Ebersberg, D 
Synemin ΔHead-Linker-R 
5’-cgcGGATCC-
TTAAAACCAATGCCCATCATTCTC-3’ 
MWG Eurofins, 
Ebersberg, D 
Synemin_301-961-F 
cccAAGCTTcg-
GTGAAGACCGGCCTCAGTCTGG 
MWG Eurofins, 
Ebersberg, D 
Synemin_301-961-R cgcGGATCC-CTCCCTCATGCGCTCGGGAAG 
MWG Eurofins, 
Ebersberg, D 
Synemin_962-1565-F 
cccAAGCTTcg-
CTTCCCGAGCGCATGAGGGAGG 
MWG Eurofins, 
Ebersberg, D 
Synemin_962-1565-R 
cgcGGATCC-
TTAAAACCAATGCCCATCATTCTC 
MWG Eurofins, 
Ebersberg, D 
Synemin_S1114A-F 
CCACAGGCTTTGCCCAGTCACAGGTGCTG-
GAGGATG-F 
MWG Eurofins, 
Ebersberg, D 
Synemin_S1114A-R 
CCACAGGCTTTGCCCAGGCACAGGTGCTG-
GAGGATG-R 
MWG Eurofins, 
Ebersberg, D 
Synemin_S1159A-F 
GCGGGAGGTGAC-
CTAGCTCAGGCAGCGAGCCCGACC-F 
MWG Eurofins, 
Ebersberg, D 
Synemin_S1159A-R 
GGTCGGGCTCGCTGCCTGAGCTAGGTCAC-
CTCCCGC-R 
MWG Eurofins, 
Ebersberg, D 
4.1.7 Polymerases, Restriction enzymes and ligases 
HotStar Plus Polymerase with the corresponding 10x PCR Buffer was used for PCR 
(Quiagen, Hilden, D). High fidelity restriction enzymes (Hind III for forward and Bam HI for 
reverse), T4 DNA ligase and appropriate buffers were purchased from NEB (Frankfurt a.M). 
4.1.8 Bacterial culture 
Competent DH5α E.coli (NEB, Frankfurt a.M., D) were cultured on LB agar plates for clone 
selection or in LB medium for bacteria growth (Table 4.7). The successful and correct PCR 
amplification and ligation into the target-vector was ensured by sequencing (Eurofins) and 
agarose-gel electrophoresis. 
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Table 4.7. Composition of media used to culture bacteria. 
Medium Composition Company 
LB medium 
10 g Tryptone 
5 g Yeast extract 
Ad 1 l H2O  
pH adjusted to 7.0 using 10 M NaOH 
AppliChem GmbH, Darmstadt, D 
AppliChem GmbH, Darmstadt, D 
 
AppliChem GmbH, Darmstadt, D 
SOC 
20 g Tryptone 
5 g Yeast extract 
0.5 g NaCl 
2.5 ml 1 M KCl 
20 ml sterile 1 M glucose 
AppliChem GmbH, Darmstadt, D 
AppliChem GmbH, Darmstadt, D 
AppliChem GmbH, Darmstadt, D 
AppliChem GmbH, Darmstadt, D 
AppliChem GmbH, Darmstadt, D 
To prepare agar plates, 1 l of LB medium was mixed with 15 g Agar (AppliChem 
GmbH, Darmstadt, D). Then the mixture was autoclaved and supplemented with selection 
antibiotics ampicillin (AppliChem GmbH, Darmstadt, D) or kanamycin (AppliChem GmbH, 
Darmstadt, D) at concentrations 100 µg/mL and 30 µg/mL respectively. 
4.1.9 Protein and DNA ladders 
Protein ladder used for SDS gel electrophoresis: 
 PageRuler Unstained (ThermoFisher Scientific, Erlangen, D);  
 HiMarkTM Pre-Sained Protein Standard (Novex®, ThermoFisher Scientific, Erlan-
gen, D).  
DNA ladder for agarose gel electrophoresis: 1 kb DNA ladder (NEB, Frankfurt 
a.M., D). 
4.1.10 Method kits 
Table 4.8. Method kits used for biochemical applications. 
Kit Application Company 
BCA Protein Assay Kit Determination of protein concentration Pierce, Bonn, D 
ECL Western Blotting 
Detection Reagents 
Western blot detection 
Amersham, Frei-
burg, D 
Proximity Ligation Assay 
Kit Duolink® 
Protein-Protein interaction 
Sigma Aldrich, 
Taufkirchen, D 
QuikChange II Site-
Directed Mutagenesis Kit 
Site directed mutagenesis 
Agilent, Waldbronn, 
D 
NucleoSpin® Gel and 
PCR cleanup kit 
Cleanup of PCR products or vectors after enzy-
matic digestion 
Macherey & Nagel, 
Düren, D 
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4.1.11 Primary antibodies 
Table 4.9. Primary antibodies used for Western blot, immunoprecipitation and immunofluorescence. 
Antibody Application Dilution Company 
ATM, rabbit, monoclonal 
Western blot 
Immunoprecipitation 
1:1000 
10 µl 
Abcam, Cambridge, UK 
ATM S1981, mouse, 
monoclonal 
Western blot 1:500 Rockland, Pennsylvania, USA 
β-Actin, Klon AC-15, 
mouse, monoclonal 
Western blot 1:10000 Sigma Aldrich, Taufkirchen, D 
DNA-PKcs, rabbit, poly-
clonal 
Western blot 
Immunoprecipitation 
1:1000 
10 µl 
Cell Signaling, Frankfurt a. M., 
D 
DNA-PKcs S2056, rabbit, 
polyclonal 
Western blot 
Immunofluorescence 
PLA 
1:500 
1:200 
1:100 
Abcam, Cambridge, UK 
c-Abl, rabbit, polyclonal 
Western blot 
immunoprecipitation 
1:1000 
10 µl 
Cell Signaling, Frankfurt a. M., 
D 
c-Abl T715, rabbit, poly-
clonal 
Western blot 1:500 
Cell Signaling, Frankfurt a. M., 
D 
c-Abl Y412, rabbit, poly-
clonal 
Western blot 
Immunoprecipitation 
1:1000 
10 µl 
Cell Signaling, Frankfurt a. M., 
D 
Ku70, mouse, monoclonal Western blot 1:1000 Abcam, Cambridge, UK 
γH2AX S139, mouse, 
monoclonal 
Western blot Immuno-
fluorescence 
1:1000 
1:200 
Millipore, Massachusetts, USA 
53BP1, rabbit, polyclonal Immunofluorescence 1:200 
Novus Biologicals, Colorado, 
USA 
Desmuslin, mouse, mon-
oclonal 
Western blot 
PLA 
1:500 
1:100 
Abcam, Cambridge, UK 
Desmuslin, rabbit, poly-
clonal 
Western blot 1:500 Abcam, Cambridge, UK 
Desmuslin, mouse, mon-
oclonal 
Immunoprecipitation 
Immunofluorescence 
3.5 µg 
1:100 
Santa Cruz, Dallas, USA 
BrdU, mouse, monoclonal FACs Analysis 1:50 BD, Heidelberg, D 
PARP1, rabbit, polyclonal Western blot 1:1000 
Cell Signaling, Frankfurt a. M., 
D 
HP1α, rabbit, polyclonal 
Western blot 
Immunofluorescence 
1:1000 
1:200 
Cell Signaling, Frankfurt a. M., 
D 
MEK1/2, rabbit, polyclo-
nal 
Western blot 1:1000 
Cell Signaling, Frankfurt a. M., 
D 
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4.1.12 Secondary antibodies 
Table 4.10. Secondary antibodies used for Western blot, immunoprecipitation, immunofluorescence or immuno-
histochemical applications. 
Antibody Application Dilution Company 
Anti-mouse IgG, HRP con-
jugated 
Western blot 1:5000 Pierce, Bonn, D 
Anti-rabbit IgG, HRP con-
jugated 
Western blot 1:5000 Pierce, Bonn, D 
Anti-mouse IgG, HRP con-
jugated 
Immunoprecipitation 1:1000 GeneTex, Irvine, USA 
Anti-rabbit IgG, HRP con-
jugated 
Immunoprecipitation 1:1000 GeneTex, Irvine, USA 
Alexa Fluor®488 
Anti-mouse IgG 
Immunofluorescence 1:200 
Life Technologies GmbH, 
Darmstadt, D 
Alexa Fluor®488 
Anti-rabbit IgG 
Immunofluorescence 1:200 
Life Technologies GmbH, 
Darmstadt, D 
Alexa Fluor®594 
Anti-mouse IgG 
Immunofluorescence 1:200 
Life Technologies GmbH, 
Darmstadt, D 
Alexa Fluor®594 
Anti-rabbit IgG 
Immunofluorescence 1:200 
Life Technologies GmbH, 
Darmstadt, D 
Alexa Flour®594  
Phalloidin 
Immunofluorescence 1:800 
Life Technologies GmbH, 
Darmstadt, D 
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4.1.13 Solutions for cell biological applications 
Table 4.11. Solutions used for cell biological applications. The detailed composition for each solution is shown. 
Substance Composition Company 
1x PBS RT Sigma Aldrich, Taufkirchen, D 
1x Trypsin/EDTA (4 °C) Sigma Aldrich, Taufkirchen, D 
1% Agarose 
1 g Agarose  
ad 100 ml ddH2O 
Sigma Aldrich, Taufkirchen, D 
10 nM Non-Essential Amino 
Acid Solution (NEAA) 
(4 °C) Sigma Aldrich, Taufkirchen, D 
80% Ethanol 
800 ml Ethanol, denatured, 
99% ad 1 l ddH2O 
Berkel, Berlin, D 
 
Cell culture medium  
DMEM with GlutaMAX™ (sup-
plemented with 10% FCS, 1% 
NEAA) 
Life Technologies, Karlsruhe, D 
MatrigelTM Basement 
Membrane High 
Concentration, Laminin rich 
Extracellular Matrix 
20 mg/ml 
(-20 °C) 
10 mg/ml, in DMEM 
(4 °C) 
5 mg/ml, in Komplettmedium 
(4 °C) 
BD, Heidelberg, D 
Coomassie stain 
100 ml Methanol 
37,5 ml Acidic acid 
0,25 g Coomassie G250 
ad 500 ml ddH2O 
Roth, Karlsruhe, D 
Merck, Darmstadt, D 
Merck, Darmstadt, D 
 
Fetal Calf Serum (FCS) 
Heat inactivated prior to use: 
30 min at 56 °C (-20 °C) 
PAA Laboratories GmbH,  
Cölbe, D 
HEPES solution 1M  Sigma Aldrich, Taufkirchen, D 
Lipofectamine2000 (4 °C) Life Technologies, Karlsruhe, D 
Oligofectamine (4 °C) Life Technologies, Karlsruhe, D 
OptiMEM with GlutaMAX™ (4 °C) Life Technologies, Karlsruhe, D 
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4.1.14 Solutions for protein-biochemical and molecular-biological applications 
Table 4.12. Solutions used for protein-biochemical and molecular-biological applications. The composition for 
each solution is shown. 
Substance Composition Company 
10% Ammonium persulfate 
(APS) 
1 g APS 
ad 10 ml ddH2O (-20 °C) 
AppliChem GmbH, Darmstadt, D 
10x Blotting buffer  
(Maniatis-SDS) 
29 g Glycine 
58 g Tris 
ad 1 l ddH2O 
Roth, Karlsruhe, D 
Roth, Karlsruhe, D 
1x Blotting buffer 
100 ml 10x Blotting buffer 
200 ml Methanol 
ad 1 l ddH2O 
Roth, Karlsruhe, D 
 
5% BSA solution 
0,5 g Bovine Serum Albumin  
ad 10 ml PBST (4°C) 
Serva, Heidelberg, D  
1x Cell Lysis Buffer 
1 ml 10x Cell Lysis Buffer 
40 µl CompleteTM protease inhibi-
tor cocktail 
ad 9 ml ddH2O 
Cell Signaling, Frankfurt a. M., D 
25x CompleteTM protease 
inhibitor cocktail 
1 Tablet 
ad 2 ml ddH2O (-20 °C) 
Roche Diagnostics GmbH, 
Mannheim, D 
GBX-Developer-Kodak 
250 ml Developer 
ad 1 l ddH2O 
Kodak, Stuttgart, D 
GBX-Fixer-Kodak 
250 ml Fixer 
ad 1 l ddH2O 
Kodak, Stuttgart, D 
10x Loading dye 
250 mg Bromphenol blue 
33 ml 150 mM Tris (pH 7,6) 
60 ml Glycerol 
ad 100 ml ddH2O (4°C) 
AppliChem GmbH, Darmstadt, D 
Roth, Karlsruhe, D  
Roth, Karlsruhe, D 
5% Milk powder  
5 g skimmed milk powder 
ad 100 ml 1x PBS (4 °C) 
AppliChem GmbH, Darmstadt, D 
Modified RIPA lysis buffer 
951 µl RIPA buffer 
40 µl 25x CompleteTM protease 
inhibitor cocktail 
5 µl 200 mM Na3VO4 
4 µl 500 mM NaF 
 
200 mM Na3VO4 
3,678 g Na3VO4 
ad 100 ml ddH2O (-20 °C) 
Sigma Aldrich, Taufkirchen, D 
500 mM NaF 
2,1 g NaF 
ad 100 ml ddH2O (-20 °C) 
Sigma Aldrich, Taufkirchen, D 
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Substance Composition Company 
20x PBS (pH 7,4) 
160 g NaCl 
4 g KCl 
36 g Na2HPO4 
4,8 g KH2PO4 
ad 1 l ddH2O 
Merck, Darmstadt, D 
Merck, Darmstadt, D 
Merck, Darmstadt, D 
Merck, Darmstadt, D 
1x PBS 
50 ml 20x PBS 
ad 1 l ddH2O 
 
PBS/0,05% Tween 20 
(PBST) 
0,5 ml Tween 20 
ad 1 l 1x PBS 
Serva, Heidelberg, D 
6x Laemmli SDS sample 
buffer  
50 ml 6x sample 
Alfa Aesar, ThermoFisher Scien-
tific, Erlangen, D 
AppliChem GmbH, Darmstadt, D 
 
RIPA buffer 
12,5 ml Tris-HCl (pH 7,4) 
2,5 ml NP-40 
6,25 ml 10% Sodium deoxychola-
te 
7,5 ml 5 M NaCl 
0,5 ml 0,5 M EDTA 
ad 250 ml ddH2O 
(4 °C) 
AppliChem GmbH, Darmstadt, D 
Fluka, München, D 
AppliChem GmbH, Darmstadt, D 
Merck, Darmstadt, D 
Roth, Karlsruhe, D 
10% SDS 
100 g SDS 
ad 1 l ddH2O 
Roth, Karlsruhe, D 
10x SDS running buffer 
30,3 g Tris 
144,1 g Glycine 
10 g SDS 
ad 1 l ddH2O 
Roth, Karlsruhe, D 
Roth, Karlsruhe, D 
Roth, Karlsruhe, D 
1x SDS running buffer 
100 ml 10x SDS running buffer 
ad 1 l ddH2O 
 
10x TBE buffer (pH 8,0) 
108 g Tris 
55 g Boric acid 
40 ml 0,5 M Na2EDTA 
ad 1 l ddH2O 
Roth, Karlsruhe, D 
Merck, Darmstadt, D 
Merck, Darmstadt, D 
0,5 M Tris buffer (pH 6,8) 
30,275 g Tris 
ad 1 l ddH2O 
Roth, Karlsruhe, D 
3 M Tris buffer (pH 8,8) 
181,71 g Tris 
ad 1 l ddH2O 
Roth, Karlsruhe, D 
Buffer I for Chromatin frac-
tionation  
0.5 ml 50 mM HEPES, pH 7.5 
0.15 ml 150 mM NaCl 
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Substance Composition Company 
0.01 ml 1 mM EDTA, pH 8.0 
25 µl 0.05% Nonidet P40 
ad 4.34 ml ddH2O 
before use add protease inhibitors 
Buffer II for Chromatin frac-
tionation 
0.5 ml 50 mM HEPES, pH 7.5 
0.15 ml 150 mM NaCl 
0.01 ml 1 mM EDTA, pH 8.0 
25 µl 0.05% Nonidet P40 
ad 4.34 ml ddH2O 
before use add protease inhibitors 
and 10 µl of 100 µg/ml RNAase 
plus Benzonase 
 
Buffer III for Chromatin frac-
tionation 
0.5 ml 50 mM HEPES, pH 7.5 
0.15 ml 150 mM NaCl 
0.01 ml 1 mM EDTA, pH 8.0 
25 µl 0.05% Nonidet P40 
ad 4.34 ml ddH2O 
before use add protease inhibitors 
 
Buffer IV for Chromatin frac-
tionation 
0.5 ml 50 mM HEPES, pH 7.5 
0.45 ml 450 mM NaCl 
0.01 ml 1 mM EDTA, pH 8.0 
50 µl 1% Triton X-100 
ad 3.64 ml ddH2O 
before use add protease inhibitors 
 
4.1.15 Solutions for immunofluorescence  
Table 4.13. Solutions used for immunofluorescence and immunohistological applications. The composition for 
each solution is shown. 
Substance Composition Company 
0,25% Triton X-100 125 µl Triton X-100 
ad 50 ml 1x PBS 
Roth, Karlsruhe, D 
1% BSA 0,5 g Bovine serum albumin (BSA) 
ad 50 ml 1x PBS 
Sigma Aldrich, Taufkirchen, D 
3% Formaldehyde 1 ml 37% Formaldehyde  
ad 11 ml 1x PBS 
Merck, Darmstadt, D 
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4.1.16 Further solutions and chemicals 
Table 4.14. Further solutions and chemicals used for biochemical, molecular-biological or in vitro applications. 
Substance Company 
30% Acrylamide bis-acrylamide solution (29:1) Serva, Heidelberg, D 
Agarose, electrophoresis grade Life Technologies, Karlsruhe, D 
Agarose, Type-A Sigma Aldrich, Taufkirchen, D 
Dimethyl sulfoxide (DMSO) AppliChem GmbH, Darmstadt, D 
Ethanol, denatured, 99% Merck, Darmstadt, D 
Formaldehyde, 37% Merck, Darmstadt, D 
G418 Sulfat (100 mg/ml in 0,1 M HEPES)  Calbiochem, Bad Soden, D 
Isopropyl alcohol Merck, Darmstadt, D 
Ponceau S Sigma Aldrich, Taufkirchen, D 
ProLong Diamant Antifade Mountant Life Technologies, Karlsruhe, D 
ProLong Diamant Antifade Mountant with DAPI Life Technologies, Karlsruhe, D 
Red SafeTM nucleic acid staining solution 
iNtRON Biotechnology, Kyungki-Do, 
Korea 
Tetramethylethylene-diamine (TEMED) Merck, Darmstadt, D 
4.1.17 PC programs 
Table 4.15. PC programs for data analysis and presentation. 
Program Company 
GraphPad Prism 7 GraphPad Software Inc., San Diego, USA 
Fiji (Schindelin et al., 2012) National Institutes of Health 
Magellan 5.0 Software Tecan, Crailsheim, D 
Microsoft Office 2010 Microsoft Corp., Redmond, WA, USA 
Zeiss LSM Image Browser Version 3,5,0,376 Carl Zeiss GmbH Jena, D 
Zeiss AxioVision SE64 Rel. 4.9 Carl Zeiss GmbH Jena, D 
FlowJo (Version 7.6.2) FlowJo LLC, Oregon, USA 
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4.2 Methods 
4.2.1 Cell culture 
Mycoplasma-free HNSCC (Cal33, FaDu, HSC4, SAS, UTSCC5, UTSCC8, UTSCC14, 
UTSCC15, UTSCC45, XF354fl) cell lines were kindly provided by R Grenman (Turku Univer-
sity Central Hospital, Finland). SKX cells were provided by M Krause (TU-Dresden, D). Sta-
bly transfected Cal33-pEJ5GFP and Cal33-pGC cells were obtained from K Borgmann 
(Hamburg, D). Cells were asynchronously cultured in Dulbecco’s modified Eagle’s medium 
containing glutamax-I and supplemented with 10 % fetal calf serum and 1 % non-essential 
AAs at 37 °C in a humidified 8.5 % CO2 incubator. Cells were grown to 70-80 % confluency, 
harvested or subcultured every 3-4 days. Splitting ratios were cell line dependent, but mainly 
1:10 was used. 
 
Table 4.16. HNSCC cells and origin 
Cell line  Origin 
Cal33 Tongue 
FaDu Hypopharynx 
HSC4 Tongue 
SAS Tongue 
SKX Floor of the mouth 
UTSCC5 Tongue 
UTSCC8 Larynx 
UTSCC14 Tongue 
UTSCC15 Tongue 
UTSCC45 Floor of the mouth 
XF354fl Floor of the mouth 
4.2.2 Cell freezing and thawing 
Adherently growing cells were trypsinized, resuspended in culture medium and centrifuged at 
130 x g for 3 min. Following centrifugation, cells were reconstituted in freezing medium 
(complete DMEM supplemented with 20 % FCS and 0.5 % DMSO), aliquoted into cryovials 
and transferred into the liquid nitrogen for the long-term storage.  
For thawing, cells were rapidly transferred into the tube with the culture medium, centri-
fuged at 130 x g for 3 min, resuspended in fresh medium, and seeded on the culture flask. 
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4.2.3 siRNA knockdown 
In order to specifically inhibit the expression of genes of interest (Table 4.3), RNA interfer-
ence technique was used (Elbashir et al., 2001; Kim, 2005). Using endoribonuclease-
prepared small interfering (esiRNA) or small interfering RNA (siRNA), the expression of the 
mRNA from the library, as well as synemin, DNA-PKcs and c-Abl were knocked down (Table 
4.3). To this end cells were plated in a 6-well plate or 100 mm Petri dish at concentrations 
3 x 105 cells or 1.2 x 106 cell per well/dish respectively. Twenty-four h after the seeding, cells 
were transfected using 26.6 nM esiRNA or 20 nM siRNA. Nonspecific control RLUC/siRNA 
(siCTRL) or specific esi- or si-RNA were diluted in OpitMEM (solution A). In parallel, a sec-
ond dilution composed of Oligofectamine/OptiMEM was prepared in a different reaction tube 
(solution B) (Table 4.17). Both dilutions were incubated for 10 min. Subsequently, A and B 
dilutions were mixed together and the final solution was incubated for 20 min. In the mean-
time, cells were washed with OptiMEM. Finally, 800 µl or 4.8 ml OptiMEM were added per 6-
well or 100 mm dish, respectively. Transfection of cells was performed using 200 µl (6-well) 
or 1.2 ml (100 mm dish) transfection mix. Following an 8 h incubation period under standard 
cell culture conditions, OptiMEM supplemented with 20 % FCS was added (1 ml per 6-well or 
6 ml per 100 mm dish). Twenty-four h after transfection, cells were used for experiments. 
 
Table 4.17. Pipetting scheme for esiRNA and siRNA transfection in 6-well plates and 100 mm dishes. 
   esiRNA dilution Oligofectamine dilution 
 csiRNA cfinal RNAi OptiMEM Oligofectamine OptiMEM 
6-well plate 20 mM 26 nM 1.33 µl 179 µl 8 µl 12 µl 
100 mm 
dish 
20 mM 26 nM 8 µl 1072 µl 48 µl 72 µl 
   siRNA dilution Oligofectamine dilution 
 csiRNA cfinal RNAi OptiMEM Oligofectamine OptiMEM 
6-well plate 20 mM 20 nM 1 µl 184 µl 4 µl 11 µl 
100 mm 
dish 
20 mM 20 nM 6 µl 1104 µl 24 µl 66 µl 
4.2.4 Inhibitor treatment and chemotherapy 
The chemotherapeutic agents cisplatin and imatinib and the inhibitors of ATM and DNA-PKcs 
were added into the cells as single compounds or in combination 1 h prior to X-ray irradia-
tion. Dilution of all inhibitors was performed in DMSO. Cisplatin was used at effective con-
centrations EC10 and EC50, which were determined by the colony formation assay. Imatinib, 
ATMi and DNA-PKcsi were applied at a final concentration of 10 µM. Substances were ap-
plied 1 h prior to irradiation. 
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4.2.5 Radiation exposure 
Cells were irradiated at RT using single doses of 200 kV X-rays filtered with 0.5 mm Cu 
(Yxlon Y.TU 320; Yxlon, Hamburg, Germany). The dose-rate was approximately 1.38 Gy/min 
at 20 mA. The absorbed dose was measured using a Duplex dosimeter (PTW, Freiburg, 
Germany) considering temperature and atmospheric pressure. Applied doses were ranged 
from 0 to 6 Gy X-rays. 
4.2.6 3D Colony formation assay 
The colony formation assay represents a gold standard for the measurement of genotoxic 
stress effects induced by ionizing radiation or cytotoxic substances. This assay, frequently 
used in radiobiology, measures the reproductive integrity of cells (Puck and Marcus, 1956). 
Cells capable to pass through five or more mitoses and being able to form colonies of at 
least 50 cells are considered clonogenic (van der Kogel, 2009). These cells, despite being 
subjected to stress, have retained their capacity to divide indefinitely. The plating efficiency 
(PE) is a parameter which indicates the percentage of seeded cells that grow into colonies 
and thereby reflects the basal cell survival (Hall and Giaccia, 2012). PE is calculated using 
this formula: 
𝑃𝑙𝑎𝑡𝑖𝑛𝑔 𝐸𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 =  
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑜𝑙𝑜𝑛𝑖𝑒𝑠
𝐶𝑒𝑙𝑙𝑠 𝑠𝑒𝑒𝑑𝑒𝑑 
× 100 
Upon irradiation or treatment with cytotoxic substances the fraction of surviving cells 
(SF) is calculated as follows: 
𝑆𝑢𝑟𝑣𝑖𝑣𝑖𝑛𝑔 𝐹𝑟𝑎𝑐𝑡𝑖𝑜𝑛 =  
𝐶𝑜𝑙𝑜𝑛𝑖𝑒𝑠 𝑐𝑜𝑢𝑛𝑡𝑒𝑑
𝐶𝑒𝑙𝑙𝑠 𝑠𝑒𝑒𝑑𝑒𝑑 ∙
𝑃𝐸
100
 
Results are presented as dose survival curves showing mean ± s.e.m. from three or 
more independent experiments, with the dose plotted on a linear scale and surviving fraction 
on a logarithmic scale (Puck and Marcus, 1956). 
Measurement of clonogenicity was performed by plating single cells (Table 4.18) em-
bedded in 0.5 mg/ml laminin-rich extracellular matrix (lrECM) in 96-well culture dishes coated 
with 50 μl of 1 % agarose to avoid cell adhesion (Eke et al., 2009),(Storch et al., 2010b). De-
pendent on the cell line a specific number of cells per-well (Table 4.18) was seeded in 100 µl 
culture medium together with 0.5 mg/ml lrECM. Cells were incubated at standard cell culture 
conditions (section 4.2.1) for 24 h allowing the matrix to polymerize. The polymerized matrix 
was covered with 100 μl of cDMEM followed by single radiation doses of 2, 4, 6 Gy or left 
unirradiated (Fig. 4.1). After the cell line specific incubation period (Table 4.18) cells were 
fixed with 50 µl of 9% FA and stored at 4 °C. Colonies with more than 50 cells were counted 
by using the inverted microscope. 
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Figure 4.1: Schematic representation of the 3D colony formation assay workflow. Cells were transfected 
with the corresponding RNAi and 24 h after resuspended and reseeded in a 3D lrECM format. Next day cells 
were irradiated and kept for couple of days at optimal conditions for the colony evaluation later on. 
 
Table 4.18. Cell numbers and corresponding incubation periods used for the colony formation assays.  
Cell line Cell numbers [0, 2, 4 and 6 Gy] Incubation [d] 
Cal33 2000 14 
FaDu 2000 9 
HSC4 2000 8 
SAS 2000 8 
UTSCC5 2000 14 
UTSCC8 3000 21 
UTSCC14 1000 8 
UTSCC15 1000 8 
UTSCC45 1000 8 
XF354fl 3000 14 
4.2.7 3D high-throughput RNAi-based screening 
High-throughput screening (HTS) is a versatile and fast approach to investigate complex bio-
logical questions. It is commonly used for the identification of novel drugs, genes or proteins 
which modulate particular biological mechanism (e.g. survival, apoptosis, DNA repair, me-
tabolism, etc). 
4.2.8 Screening development 
For the 3D high-throughput RNAi-based screening (3DHT-RNAi-S) development, firstly the 
library was designed based on the Integrin Adhesome containing all the main focal adhesion 
(FAPs) proteins present in cells. To do so, 117 FAPs were selectively chosen based on the 
review from Horton et al., 2015, leaving out receptor tyrosine kinases and transcription fac-
tors. On Table 4.19, it is possible to observe all the FAPs that were used for this screen. The 
library was purchased from Eupheria Biotech. 
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Once the library was ready, it was necessary to automatize and improve the protocol for 3D 
colony formation and foci assay. To do so, a special cell line containing pEGFP-53BP1-C1 
plasmid was generated for fast quantification of foci. During the generation of the pEGFP-
53BP1-UTSCC15 cells, optimization of several parameters was needed: 
1. Number of cells to be seeded before transfection (7500, 10000 and 15000 cells per 
96-well) 
2. Amount of trypsin needed (10, 20, 30 or 50 µl per 96-well plate) 
3. Amount of needed medium for resuspension after trypsinization (100, 150, 170 or 
200 µl per 96-well) 
4. Number of cells post detachment (evaluation of cell numbers and good detachment) 
5. Correct dilution in order to have a homogenous suspension for CFA and residual 
DSB. 
 
Table 4.19. List of focal adhesion proteins selected for the screen library according to the Integrin Adhesome 
described by Horton et al., 2015. 
ACTB FBLIM1 ITGA9 KIF11 PARVA SSH3BP 
ACTN1 FERMT3 ITGAD KTN1 PARVB SVIL 
ARPC2 FHL2 ITGAE LASP1 PFN1 SYNM 
BCAR1 FLNA ITGAL LDB3 PKD1 TENC1 
C20orf42 GAB1 ITGAM LIMS1 PLEKHC1 TES 
CALR GNB2L1 ITGAV LIMS2 PPFIA1 TGFB1I1 
CASS4 GRB2 ITGAX LPP PVR THY1 
CAV1 GRB7 ITGB1 LPXN PXN TLN1 
CD151 HAX1 ITGB1BP1 LRP1 RDX TNS1 
CD47 IRS1 ITGB2 MSN RLUC TRIP6 
CEACAM1 ITGA1 ITGB3 NCK2 SDC4 TRPM7 
CFL1 ITGA10 ITGB3BP NDEL1 SDCBP VASP 
CORO1B ITGA11 ITGB4 NEDD9 SH2B1 VCL 
CORO2A ITGA2 ITGB5 NEXN SH3KBP1 VIL2 
CRK ITGA3 ITGB6 NF2 SHC1 ZFYVE21 
CRKL ITGA4 ITGB7 NRP1 SLC3A2 ZYX 
CSRP1 ITGA5 ITGB8 NRP2 SMPX 
CTTN ITGA6 JUB NUDT16L1 SORBS1 
ENAH ITGA7 KCNH2 OSTF1 SORBS2 
ENG ITGA8 KEAP1 PALLD SORBS3 
 
Once all the parameters were optimized, the workflow of the 3DHT-RNAi-S (Fig. 5.1) 
consisted of the evaluation of CFA and residual DSB after FAPs knockdown in combination 
of 0 or 6 Gy X-rays. 
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4.2.9 3D high-throughput screen using esiRNA (3D HTP-RNAi-S) 
Subsequent to the variables optimization, the extended protocol included the following steps. 
In the first day, 15000 UTSCC15 cells, stably expressing pEGFP-53BP1-C1, were 
seeded per 96-well. Twenty-four h after, transfection was performed using a master-mix 
composed by 18.6 µl of OptiMEM, 1µl of esiRNA (with a final concentration of 10 ng) and 0.4 
µl of Oligofectamine per well. Before adding the solution, cells were washed with OptiMEM 
and subsequently, 30 µl of OptiMEM was added. After that, 20 µl of the master-mix was add-
ed. Eight h post incubation, 50 µl of OptiMEM containing 10% FCS was added to the cells. 
Next day, cells were trypsinazed with 30 µl of trypsin and resuspended with 170 µl of 
cDMEM. From this suspension, 50 µl were used for the CFA (plus 50 µl matrigel (5 mg/ml, 
with a final concentration of 0.5 mg/ml) and 400 µl cDMEM) and 75 µl was used for the re-
sidual DSB evaluation (plus 30 µl matrigel (5 mg/ml, with a final concentration of 0.5 mg/ml) 
and 195 µl cDMEM). Everything was well mixed in 96 deep-well plates. 
From the master-mix, 100 µl were then transferred in 96-well plates pre-coated with 1% 
agarose. Next day cells were irradiated with 6 Gy X-rays or left untreated. The residual num-
ber of foci was evaluated 24 h post irradiation, while clonogenic survival was measured after 
8 d of incubation as published in (Dickreuter et al., 2016b). Cell colonies (>50 cells) were 
counted. 
4.2.10 Immunofluorescence staining 
Immunofluorescence is a technique to visualize the localization of proteins of interest based 
on the specificity of antibody-antigen interactions. A primary antibody is used to specifically 
bind a protein of interest and a fluorophore-coupled secondary antibody directed against the 
primary antibody is used for detection. Using a fluorescence microscope or a laser scanning 
microscope the localization of the protein can be visualised. 
To analyze endogenous localization of synemin in HNSCC cell lines, 40 x 105 HNSCC 
cells were grown on glass coverslips. Twenty-four h after the seeding cells were fixed with 
3 % Formaldehyde. Following fixation step, coverslips were washed 3 times with ice cold 1x 
PBS and permeabilized with 0.25% Triton-X-100/PBS for 10 min at RT. After that the wash-
ing step cells were blocked with 1 % BSA/PBST for 1 h at RT and incubated with specific 
primary antibody overnight at 4 °C. Subsequently, fluorophore-coupled secondary antibodies 
or fluorophore-coupled-Phalloidin (for F-actin staining) were applied for 1 h at RT. Finally, 
cells were washed three times with 1x PBS and mounted using ProLong Diamant Antifade 
Mountant with DAPI. Images were acquired using LSM510meta (Zeiss). 
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4.2.11 Foci assay 
To analyze DNA damage, we performed immunofluorescent staining for γH2AX, 53BP1 and 
DNA-PKcs S2056. Previously it has been shown that 53BP1, phosphorylated histone H2AX 
and DNA-PKcs phosphorylated at Serine 2056 are strictly associated with DNA damage and 
form foci at the DSB sites (Fig. 4.2) (Koppenhagen et al., 2016). For further determination of 
DSBs, co-localized foci of γH2AX and 53BP1 (Löbrich et al., 2010) were analyzed. In the 
current part of the study, we investigated foci kinetic after 30 min, 1h, 2h, 6h, and 24 h post 
irradiation. For the evaluation of residual foci (the damages that cannot be repaired) cells 
were fixed 24 h post irradiation. 
 
Figure 4.2: Schematic representation of a DSB marked by γH2AX and 53BP1. Phosphorylation of H2AX and 
binding of 53BP1 to the DNA occurs immediately after the DSB induction. Then, when NHEJ prevails over HR, 
Ku70/Ku80 complex get recruited at the damage, followed by DNA-PKcs which overactivates itself with a feed-
back S2056 autophosphorylation. 
 
 2D Foci assay  
Cells were seeded and immunostained as described in section 4.2.10. The list of anti-
bodies used for the staining shown in Tables 4.9 and 4.10. 
 3D Foci assay 
For the 3D culture, 24-well plates were coated with 250 μl of 1 % agarose to avoid cell 
adhesion. For each condition, we seeded 5 x 104 cells per well embedded in 0.5 mg/ml of 
IrECM. After the plating, cells were treated with a single dose of 6 Gy X-rays (non-irradiated 
cells were used as a control) and fixed 24 h after irradiation (Fig. 4.3). For the fixation proce-
dure, cells were transferred into the 15 ml Falcon tube with PBS, centrifuged at 300 x g, 4 °C 
for 3 min and incubated with trypsin/EDTA for 10 min at 37 °C in the bacteria shaker. After 
another centrifugation step (300 x g, 4 °C for 5 min) cells were resuspended and incubated in 
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3 % formaldehyde for 10 min at RT. Finally, the fixed cells were washed with PBS and per-
meabilized with 0.25 % Triton X-100 for 10 min at RT. Following the washing step, 1 % BSA 
blocking solution was applied for 1 h at RT and cells were incubated with the primary anti-
γH2AX,-53BP1 or -DNA-PKcs S2056 antibodies overnight at 4 °C. After the incubation cells 
were washed with PBS and re-probed with secondary antibodies for 1 h at RT in darkness. 
Thereafter samples were washed with PBS and centrifuged 2 times. Finally, 15 μl of cell 
suspension was mounted on a microscope slide using DAPI-containing Vectashield® mount-
ing medium (Vector Laboratories, California, USA). Nuclei were analyzed using a fluores-
cence microscope with a 40 x magnification. The number of γH2AX, 53BP1 and DNA-PKcs 
S2056 foci were counted in 50 nuclei per condition. 
 
Figure 4.3: Foci assay workflow. Cells were transfected with the corresponding RNAi. 24 h after the cells were 
resuspended and reseeded in a 3D lrECM format. Next day cells were irradiated and 24 h after cells were fixed 
and stained for foci detection. 
 
4.2.12 Total protein extracts, SDS-PAGE and Western Blotting 
4.2.12.1 Cell lysates 
In order to isolate proteins, cells cultured in 2D conditions were washed once with ice cold 1x 
PBS, lysed in 1xRIPA lysis buffer and detached from the dish using a cell scraper To lyze 
cells grown in 3D, 3 times concentrated RIPA buffer was applied. For the 3D a condition, 24-
well plates were coated with 250 μl of 1 % agarose to avoid cell adhesion. For each condi-
tion, 1 ml consisting of 5 x 104 cells embedded in 0.5 mg/ml were seeded per well. At the 
proper time point for lysis, 200 µl of cells cultivated in lrECM were transferred to a 1.5 ml Ep-
pendorf tube. Rapidly after, cells were lysed with 100 µl of 3xRIPA lysis buffer.  
For both 2D and 3D cell cultures, cell lysates were incubated on ice for 30 min. and 
thereafter passed through the insulin syringe in order to break the nuclear membranes. Then, 
the samples were incubated for 1 h on ice followed by centrifugation for 20 min at 16,000 x g, 
4 °C. Finally, the supernatants were transferred to the new 1.5 ml reaction tubes. At this step 
samples could be stored at -80 °C. 
For the 2D samples, protein concentration was determined using the BCA Protein As-
say Kit according to the manufacturer's instructions. Using a microplate reader together with 
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the Magelan 5.0 software, the absorption of standard series and samples were measured 
and the protein concentration was calculated. For 3D samples, protein concentration was 
determined through western blot and immunoblotting of β-actin as described in the following 
section. 
4.2.12.2 SDS-Polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS-PAGE, developed by Laemmli (1970), is used to separate proteins of a whole cell ly-
sate according to the molecular weight of proteins. Gels for SDS-PAGE were prepared using 
the Hoefer Mini gel system. Based on the molecular weight of the target proteins, different 
separation gels with varying acrylamide concentrations (4 %, 8 %, 10 % and 12 %) were 
prepared (Table 4.20). For all separations, 5 % stacking gels were used. 
25 µg of protein was mixed with 6x loading dye and incubated at 99 °C for 5 min to de-
nature high order protein structures. Next, samples and protein ladder were loaded into poly-
acrylamide gels and separated by electrophoresis with a current of 35 mA per gel. 
 
Table 4.20. Composition of stacking and separation gels used for SDS PAGE. 
Stacking gel 
5 % 
[ml] 
Separation gel 
4 % 
 [ml] 
8 % 
 [ml] 
10 % 
[ml] 
12 % 
[ml] 
ddH2O 1,63 ddH2O 2,83 2,16 1,83 1,5 
0,5 M Tris/HCL pH 
6,8 
0,72 
3 M Tris/HCL pH 
8,8 
1,25 1,25 1,25 1,25 
Acryl amide 30 % 0,5 Acryl amide 30 % 0,67 1,33 1,67 2,00 
50 % Glycerol 0,06 50 % Glycerol 0,10 0,10 0,10 0,10 
10 % SDS 0,03 10 % SDS 0,05 0,05 0,05 0,05 
10 % APS 0,06 10 % APS 0,10 0,10 0,10 0,10 
TEMED 0,0048 TEMED 0,004 0,004 0,004 0,004 
4.2.12.3 Western Blot 
The electrophoretically separated proteins were transferred onto a nitrocellulose membrane 
using a semi dry blotter Hoefer, TE77X at 35mA per gel for 3h. In detail, the stacking gel was 
removed from the glass and 6 sheets of Whatman paper as well as one sheet nitrocellulose 
membrane were soaked with 1x blotting buffer. The different components were assembled 
as shown in Figure 4.4Fehler! Ungültiger Eigenverweis auf Textmarke.. Proteins were 
transferred for 3 h using a current of 35 mA (0.8 mA pro cm2) per membrane. Following pro-
tein transfer, membranes were incubated with the PonceauS solution, a negatively charged 
dye, which reversibly binds to the protein AAs. Subsequently, membranes were destained in 
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1x PBS and blocked for 1 h in 5 % milk powder or 5 % BSA solution according to the instruc-
tions of antibody manufacturers. 
 
Figure 4.4: Scheme of the Western blot setup. Whatman paper and nitrocellulose membrane were soaked with 
1x blotting buffer. Three sheets of Whatman paper were placed on the anode and covered with the nitrocellulose 
membrane followed by the gel. Finally, 3 sheets of Whatman paper and the cathode were placed on top. 
 
Then membranes were treated with primary antibodies overnight at 4 °C under contin-
uous rotation. After the incubation step, membranes were washed 4x for 10 min in PBST and 
horseradish peroxidase-conjugated (HRP) secondary antibodies were applied for 1.5 h at 
RT. Finally, membranes were washed in PBST (5 x 10 min) and PBS (1 x 10 min) and incu-
bated for 3 min with the ECL Western Blotting Detection system. Chemiluminescent signals 
were detected by using X-ray films exposed to the prepared membrane. X-ray films were 
developed, fixed, washed in water and air-dried. Then the films were scanned and densito-
metric analysis of western blot bands was performed using the ImageJ Fiji software. Protein 
band intensity was then normalized to β-actin (for total protein) or total protein expression (for 
analysis of phosphorylations). 
4.2.13 DRGFP and EJ5GFP-based chromosomal break reporter assay 
To study the activity of HR and NHEJ, we utilized DRGFP- and pimEJ5GFP-based reporter 
assays (Bennardo et al., 2008; Krajewska et al., 2013). The reporter pimEJ5GFP plasmid 
(Fig. 4.5) contains two I-SceI sites in the 5′ untranslated region of the GFP transcript and an 
artificial start codon (ATGart) inserted between both I-SceI sites, which prevents GFP trans-
lation. I-SceI cleavage removes the artificial ATG. Subsequent rejoining of the free DNA ends 
via NHEJ reactivates translation and leads to green fluorescence. 
In case of the DRGFP reporter plasmid, the substrate is composed of two differentially 
mutated GFP genes oriented as direct repeats and separated by puromycin N-
acetyltransferase gene (a drug selection marker). One of the GFP genes, SceGFP, is mutat-
ed in order to be recognized by the rare-cutting I-SceI endonuclease, which generates DSB 
upon expression. The second GFP gene is truncated and used to repair SceGFP in case of 
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HR-mediated DSB repair, which results in the generation of one functional GFP copy detect-
able by flow cytometry (Fig. 4.5). 
HNSSC cell line Cal33 was stably transfected with DRGFP and pimEJ5GFP plasmids 
as previously published (Pierce et al., 1999). In order to measure HR/NHEJ-mediated repair, 
control and synemin esiRNA-treated cells were transiently transfected with pcDNA3BMyc-
NLS-ISceI plasmid (hereafter designated as I-SceI plasmid) by the use of Lipofectamine 
2000 according to the manufacturer’s protocol. In parallel with I-SceI, the pEGFP-N1 plasmid 
(hereafter designated as pN1 plasmid) (Clontech) was introduced to determine transfection 
rates. Four h after the transfection with I-SceI and pN1 plasmids, cells were trypsinized and 
embedded into 0.5 mg/ml lrECM. In case of the synemin overexpressing cells (mCherry-
Synemin and mCherry-C1), mCherry-Synemin plasmid or control mCherry-C1 plasmid were 
introduced together with the pN1 and I-SceI plasmids using Lipofectamine 2000 according to 
manufacturer's instructions. Cal33 cells were then reseeded in 3D, trypzinized at 72 h and 
subjected to the flow cytometry analysis (BD LSRII flow cytometer; Beckton Dickinson). 2 x 
104 events were measured per sample. GFP positive cells were normalized to pEGFP-N1-
positive cells. Data analysis was performed using FlowJo software (version 7.6.2). 
 
Figure 4.5: Schematic representation of the EJ5GFP and the pGC reporter plasmid. EJ5GFP contains two I-
SceI sequences inserted into the 5′ region that cannot be translated into the GFP transcript. Once the sequence 
gets excised, the plasmid will get ligated by NHEJ and the GFP sequence will be read and expressed. DRGFP 
plasmid has two mutated GFP genes oriented as direct repeats and separated by a puromycin gene. One of the 
GFP mutated genes will get resected by the endonuclease and the second one will be subjected to end resection 
and repair by HR. The result of both assay will lead to one functional GFP copy. Modified according to Bennardo 
et al., 2008. 
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4.2.14 Cell Cycle analysis 
Cell cycle analysis was performed using the 5-bromo-2-deoxyuridine( BrdU) incorporation 
assay. BrdU is a thymidine analog which integrates into DNA of cells during the S- phase of 
the cell cycle. To determine the number of cells in G1/G0, S and G2 phases control and 
synemin-deficient SAS cells with and without irradiation were cultured for 24, 48 and 72 h. 
Then BrdU solution (BD Biosciences) was added into the cells at concentration 10 mM 10 
min before cell detachment (1x trypsin/EDTA) and fixation (80 % ice-cold ethanol). Following 
washing step with cold PBS, cells were incubated for 10 min with 0.01 % RNase A (Sigma-
Aldrich), treated with 2 N HCl (Sigma-Aldrich) for 30 min and permeabilized with 0.5 % Tri-
ton-X-100/PBS (Carl Roth GmbH). Subsequently, mouse anti-BrdU antibodies and propidium 
iodide (Sigma-Aldrich) were added to analyze BrdU incorporation and total DNA content. Cell 
cycle distribution was determined by using FACs CantoTM II with the FlowJo software (ver-
sion 7.6.2). 
4.2.15 Kinome analysis 
Kinase activity analysis in cells upon synemin knockdown and irradiation was performed us-
ing the phosphotyrosine kinase (PTK) and serine-threonine kinase (STK) microarrays 
(PamGene). Each array contained 140 (STK) and 144 (PTK) peptides with known phosphor-
ylation sites. For each condition, 12-well plates were coated with 400 μl of 1 % agarose to 
avoid cell adhesion. After synemin depletion using esiRNA, 1 ml consisting of 1.5 × 106 cells 
embedded in 0.5 mg/ml lrECM, were plated per well. The next day cells were treated with 6-
Gy X-ray or left unirradiated. Cells were lyzed with 10x kinase buffer (#9802, Cell Signaling), 
supplemented with HALT phosphatase and protease inhibitor cocktail (#1862495 and 
#1862209, Thermo Scientific) at 1 and 24 h after 6Gy X-ray treatment (non-irradiated cells 
were used as a control). Using a 200 µl pipette, cells clusters were collected from the lrECM 
and transferred to a 1.5 ml Eppendorf tube. Rapidly after, cells were lysed with 100 µl of 3x 
lysis buffer. The lysate was then resuspended using an insulin syringe and keep on ice for 30 
min. After that, they were centrifuged for 20 min at 16,000 x g and 4 °C. The supernatant was 
removed and transferred to a new 1.5 ml reaction tube. Snap-frozen samples were sent to 
the Genomics and Proteomics Core Facility Microarray (German Cancer Research Center, 
Heidelberg) for analysis of kinase activity on a Pamstation 12 System (Pamgene). In brief, 
the arrays were blocked with 2 % BSA in water for 30 cycles and washed 3 times with PK 
assay buffer. Kinase reactions were performed for 1 h at 30 °C. Phosphorylated peptides 
were detected using fluorescence labeled antibodies (anti-rabbit–FITC) FITC-labeled arrays 
were then imaged using a 12-bit CCD camera. BioNavigator software (PamGene Interna-
tional BV) was employed for quantification of the images obtained from the phosphorylated 
arrays. A list of significantly phosphorylated peptides was generated from the control and 
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knockdown samples and analyzed with GeneGo, PhosphoSite database and KinMap to pre-
dict main down/upregulated kinases. The experiments were performed in triplicate. 
4.2.16 Immunoprecipitation 
Immunoprecipitation is a well-established and widely used technique for the detection and 
analysis of protein-protein interactions. This method is based on precipitation of the antibody-
protein complex out of a cell lysate using protein A/G-beads. Subsequently, protein interac-
tome can be characterized by western blotting or mass spectrometry.  
For the analysis of endogenous protein-protein interactions, SAS and SKX cells were 
harvested using 10x cell lysis buffer (Cell Signaling) diluted in ddH2O and supplemented with 
40 µl/ml Complete protease inhibitor cocktail. The total protein amount was measured by the 
BCA assay. Then, cell lysates were pre-cleaned with Protein A/G sepharose slurry 
(50 % v/v). Briefly, the lysate-bead solution was rotated at 4 °C for 1 h, and centrifuged at 
500 x g for 5 min. Next, the supernatant was transferred to a new reaction tube and incubat-
ed with primary antibodies (IgG as isotype control) for 1 h at 4 °C under continuous rotation. 
Subsequently, 100 μl of Protein A/G sepharose slurry (50 % v/v) was added to the samples 
and rotated overnight at 4 °C. Immunoprecipitates were washed 3 times with cold lysis buff-
er. Whole cell lysates and immunoprecipitated proteins were boiled in 50 μl sample buffer, 
separated by SDS-PAGE, transferred, and blotted. Protein precipitates were analyzed with 
specific primary antibodies as indicated. 
4.2.17 Chromatin fractionation 
This assay is used for the extraction of chromatin-bound proteins that can then be quantified 
with western blot. The protocol is based on the publication from Cheng et al. published on 
Nucleic Acid Research in 2011. In brief, 1.5 x 106 SAS cells were seeded on 100 mm dishes. 
One of the dishes was left un-irradiated and the other 2 underwent to 6 X-ray treatment. At 
the appropriate time point, cells were trypsinized and collected in a 15 ml Falcon tube, centri-
fuge at 150 x g (at 4 °C for 3 min). After the supernatant was removed, the pellet was resus-
pended in 200 µl of buffer I and let it incubate for 5 min on ice. Then the sample was centri-
fuged at 1000 x g for 5 min. The supernatant was transferred in a 1.5 ml labeled reaction 
tube. Next, the pellet was resuspended in 200 µl of buffer II. After 10 min of incubation at RT, 
the sample was centrifuged for 5 min at 1000 x g. After removing the supernatant, the pellet 
was further resuspended in 200 µl of buffer III and left it for 40 min on ice. Next, the sample 
was centrifuged at 16000 x g for 5 min. Finally, the pellet was resuspended in 200 µl of buffer 
IV and sonicated two times for 15 seconds. The lysates were then stored in the -80 °C and 
later used for western blot analysis. 
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4.2.18 Expression constructs, site-directed mutagenesis and transfection of 
plasmids 
4.2.18.1 PCR  
Fluorescent proteins were generated by PCR amplification (Table 4.5) of synemin gene with 
the addition of restriction sites, restriction digest of PCR product and desired expression vec-
tor (Table 4.22) followed by ligation. List of the primers is provided in Table 4.6. Products 
were purified using the NucleoSpin® Gel and PCR clean up kit according to the manufactur-
er’s instructions. 
 
Table 4.21. PCR protocol used to amplify genes of interest and add flanking restriction sites. 
Reagent Required concentration Amount per PCR tube 
PCR buffer (10x) 1x 5 µl 
dNTP 10 mM 1 µl 
ForwardPrimer 10 μM 1 µl 
Reverse Primer 10 μM 1 µl 
MgCl2 25 mM 1.25 µl 
HotStar Plus Polymerase 5 units/μl 0.25 µl 
cDNA 500 ng/µl Plasmid dependent 
H2O  Ad 50 µl 
Truncated synemin constructs (mCherry-Synemin ΔLinker-Tail, mCherry-Synemin 
ΔHead-Linker, mCherry-Synemin_301-961 and mCherry-Synemin_962-1565) were generat-
ed by PCR-based amplification from expression plasmids, with specific primers (Table 4.6). 
Constructs were flanked with Kpn I and Bam HI restriction sites and inserted into the Kpn I 
and Bam HI sites of pmCherry-C1.  
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Table 4.22. Protocol for restriction digest of PCR-products flanked with restriction sites and desired expression 
vectors. High fidelity restriction enzymes (NEB, Frankfurt a.M., D) were applied. 
Reagent Volume 
Purified PCR product 30 µl 
Vector 10 µg Vector dependent 
CutSmart 10 µl 
Enzyme I 3.5 µl 
Enzyme II 3.5 µl 
ddH2O ad 100 µl 
 
Table 4.23. Protocol for ligation of PCR-products flanked with restriction sites and desired expression vectors. 
The NEB cloner/Ligation calculator was used to calculate the amount of purified PCR product necessary to 
achieve a vector:insert ratio of 1:3 or 1:5. 
Reagent Self-ligation control Amount per PCR tube 
1:3 1:5 
Purified Vector 1 μl 1 μl 1 μl 
Purified PCR product 0 μl Dependent on size of PCR product 
and vector (calculated with NEB 
cloner) 
Ligation Buffer 2 μl 2 μl 2 μl 
T4 DNA Ligase  1 μl 1 μl 1 μl 
ddH2O 16 μl ad 20 μl ad 20 μl 
4.2.18.2 Transformation 
Plasmid transformation into the competent DH5α E.coli (NEB, Frankfurt a.M., D) was per-
formed using the heat shock method. Briefly, 50 µl competent cell suspension was thawed 
and incubated with 2 µl plasmid DNA for 30 min on ice. Subsequently, bacteria were heated 
to 45 °C for 42 s followed by 2 min incubation on ice. After transformation, 950 µl SOC medi-
um was added and bacteria were incubated for 2 h at 500 rpm and 37 °C in a thermomixer. 
Next, 200 µl bacteria suspension were seeded in agar plates containing either Ampicillin or 
Kanamycin for selection of successfully transformed clones. After 24 h incubation at 37 °C, 
positive clones were selected and transferred into a 15-ml centrifuge tube containing 5 ml 
selection medium and incubated for 6 h at 37 °C using a bacterial shaker. Subsequently, 4 
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ml of the pre-culture were added to 200 ml selection medium and incubated overnight at 37 
°C using a rotary shaker. Plasmid DNA was isolated using the NucleoSpin® Plasmid Easy-
Pure kit according to the manufacturer’s instructions and correct integration of the insert-DNA 
into the desired vector was verified by sequencing. 
4.2.18.3 Site-directed mutagenesis 
Mutation of the putative synemin phosphorylation sites by ATM (S1114 and S1159) predicted 
by GSP was performed using the QuikChange II Site-Directed Mutagenesis Kit according to 
manufacturer’s instructions with specific primers listed in Table 4.6. Putative synemin phos-
phorylation sites were modified by mutation of serine residues to alanine (S1114 and S1159). 
The presence of mutated sites was confirmed by sequencing. 
4.2.18.4 Plasmid transfection 
Cal33-pimEJ5GFP and Cal33-DRGFP were transiently transfected with pcDNA3-Myc-NLS-
ISceI and pEGFP-N1 plasmids. In brief, 5 x 105 cells or 1.5 x 106 cells were plated on a 6-
well plate or 100 mm Petri dish respectively. Twenty-four h after the seeding, cells were 
transfected using 4 µg or 24 µg of plasmid. The plasmid was diluted in OpitMEM (solution A). 
In parallel, a second dilution composed of Lipofectamine 2000/ OptiMEM was prepared in a 
different reaction tube (solution B) (Table 4.24). Both dilutions were incubated for 5 min. 
Subsequently, A and B dilutions were mixed together (1:1) and the final solution was incu-
bated for 20 min. In the meantime, cells were washed with cDMEM. Finally, 1 ml or 5 ml of 
cDMEM was added per 6-well or 100 mm dish respectively. Transfection of cells was per-
formed using 500 µl of transfection mix for the 6-well plate well and 3 ml for the 100 mm dish. 
Following 5 h incubation period, cells were washed and supplemented with normal growth 
medium. Similarly, SAS cells were transiently transfected using the following plasmids: 
mCherry-C1, mCherry-Synemin, mCherry-Synemin ΔLinker-Tail, mCherry-Synemin ΔHead-
Linker, mCherry-Synemin_301-961, mCherry-Synemin_962-1565, mCherry-
Synemin_S1114A and mCherry-Synemin_S1159A). 
 
Table 4.24. Pipetting scheme for plasmid transfection in 6-well plates and 100 mm dishes. 
 DNA dilution Oligofectamine dilution 
 DNA OptiMEM Oligofectamine OptiMEM 
6-well plate 4 µg 250 µl 10 µl 250 µl 
100 mm dish 24 µl 1.5 ml 60 µl 1.5 ml 
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4.2.19 2D-Proximity Ligation Assay 
The Proximity Ligation Assay is a well-described method to study protein-protein interactions 
and to identify their subcellular localization (Fig. 4.6). Briefly, 4 × 105 cells were irradiated 
with 6 Gy X-rays one day after the plating on coverslips. At 1 h post irradiation, cells were 
fixed with cold methanol for 15 min at -20 °C and incubated with primary antibodies (Des-
muslin, Ab211630 and c-Abl 2862P or Desmuslin, Ab211630 and DNA-PKcs S2056, 
ab18192) overnight. Thereafter PLA assay was performed according to the manufacturer’s 
protocol using the Duolink® PLA – protein detection kit with PLA PLUS and MINUS Probes 
for mouse and rabbit (DUO92101-1KT, Sigma-Aldrich®). Samples were analyzed using the 
Axioimager M1 (Carl Zeiss Inc.) fluorescent microscope with a magnification of 40 x. 
Figure 4.6: Principle of Proximity Ligation Technique. Protein A (mouse) and Protein B (rabbit) are recognized 
by specific primary antibodies. Subsequently, species-specific secondary antibodies (anti-mouse and anti-rabbit) 
bind to the primary antibodies. Short DNA strands are attached to the PLA samples. If the 2 proteins are in close 
proximity (<40 nm), the DNA oligonucleotides will be able to hybridize and the enzyme will form a close ligated 
circle. During amplification, the oligonucleotide sequences are amplified, generating a repeated product. Com-
plementary, fluorescently labeled oligonucleotides can bind and become microscopically detectable at a wave-
length of 594 nm. A red signal represents a protein-protein interaction (picture modified from OLINK, Sweden; 
www.olink.com, accessed June 2014). 
 
4.2.20 Statistics 
The statistical analysis was performed using GraphPad Prism 5 software. All data are pre-
sented as a mean +/- s.e.m. of at least three independent experiments. The significance of 
data was determined using two-tailed Student’s t-test. P-values of less than 0.05 are consid-
ered statistically significant. 
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5 Results 
5.1 3D high-throughput RNAi-based screening 
5.1.1 Uncovering novel radioresistance-related focal adhesion proteins 
To identify novel FAPs modulating radioresistance and DSB repair in HNSCC, a 3D lrECM 
high-throughput RNAi-based screen (3DHT-RNAi-S) depleting 117 FAP was designed and 
performed in UTSCC15 cell line stably expressing EGFP-53BP1 (UTSCC15_EGFP-53BP1) 
(Fig. 5.1 and Table 4.19). The screen was carried out under 3D culture system providing a 
physiological relevant condition compared to 2D cell culture system. 
The outcome of 3DHT-RNAi-S provided a consistent and extensive data set (Fig. 
5.2a,b and 5.3), allowing to identify several potential protein candidates (Fig. 5.2a,b and 5.3). 
The association between FAPs, such as β1 integrin, LIMS1, FAK, and FHL2 and resistance 
to cancer therapy was previously reported (Eke et al., 2012b; Hehlgans et al., 2012; Rossow 
et al., 2015; Zienert et al., 2015). In the present study depletion of integrins α5, β3, β5, as 
well as TRIP6, OSTF1, ITGB3BP, PLEKHC1 and zyxin in UTSCC15_EGFP-53BP1 cells 
remarkably enhanced basal clonogenicity. Interestingly, all integrins which affected the plat-
ing efficiency possessed the tripeptide Arg-Gly-Asp (RGD) motif (Takagi, 2004) (Fig. 5.2a 
and 5.4a). In contrast, a reduction in basal clonogenicity upon knockdown of moesin and 
KIF-11 was observed (Fig. 5.2a and 5.4a). On the next step, clonogenic survival of 
UTSCC15_EGFP-53BP1 cells exposed to 6 Gy X-rays was analyzed, which showed no 
overlap with the results of the basal survival except for KIF-11 and moesin. These data 
demonstrated that esiRNA silencing of parvin β, GRB7, vinculin, sorbin and SH3 Domain 
Containing 2 (SORBS2), and integrin α1 significantly enhanced cellular radiosensitivity (Fig. 
5.2b and 5.4b), while knockdown in SLC3A2 and CSRP1 mediated remarkable radiore-
sistance (Fig. 5.2b and 5.4b). 
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Figure 5.1: Identification of focal adhesion proteins affecting cell survival, radiosensitivity and DNA re-
pair. Workflow of 3D high-throughput RNAi screening (3D HTP-RNAi-S). 
 
Residual 53BP1-GFP foci were measured as readout for DSB repair capacity in (un-) 
irradiated UTSCC15_EGFP-53BP1 (Fig. 5.3) upon knockdown of the 117 FAPs. Depletion of 
several FAPs such as integrin αV, α7, α8, α11, and β8 subunits as well as kelch like ECH 
associated protein 1 (KEAP1), LDB3, TGFB1, and SDCBP resulted in a significant increase 
in the number of 53BP1-GFP foci after irradiation as compared to the control cells (Fig. 5.3 
and 5.4c). Remarkably, the numbers of endogenous 53BP1 foci (in non-irradiated cells) re-
mained unaffected (Fig. 5.3). Correlation analysis between the number of 53BP1 foci/cell and 
clonogenic radiation survival were performed revealing a list of potential FAPs (integrin α1 
and α7, endoglin, SDCBP, KEAP1, synemin, and talin 1) contributing to enhanced radiosen-
sitivity and impaired DSB (Fig. 5.4d). Additionally, depletion of several FAPs (e.g. vinculin, 
nexin, meosin) led to an enhancement of cellular radiosensitivity without affecting 53BP1 
foci/cell. This effect could be associated with alternative pro-survival mechanisms. Altogeth-
er, these results imply that a perturbed function in several FAPs significantly affects both ra-
diation survival and DSB repair. Moreover, the 3D-HT-RNAi-S resulted to be a robust screen-
ing platform for the identification of the new potential regulators of cellular radiation survival 
and DSB repair. 
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Figure 5.2: Identification of focal adhesion proteins affecting cell survival and radiosensitivity. a, Plating 
efficiency of 3D lrECM cell cultures with indicated knockdown (n = 4). b, Surviving fraction of 3D lrECM cell cul-
tures with indicated knockdown and 6 Gy X-rays (n = 4). Data are represented as mean ± SD (two-sided t-test; 
*P<0.05, **P<0.01, ***P<0.001). 
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Figure 5.3: Identification of focal adhesion proteins affecting DNA repair. a, Residual 53BP1 foci numbers in 
6-Gy irradiated, FAPs knockdown cells (grey) and non-irradiated controls (white). Main identified candidates from 
our screen are outlined in grey area. Data are represented as mean ± SD. 
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Figure 5.4: Identification of focal adhesion proteins affecting cell survival, radiosensitivity and DNA re-
pair. a, Enhancement ratios of cell cultures in response to FAP knockdowns (n = 4). b, Enhancement ratios of 
FAP knockdown cell cultures exposed to 6 Gy X-rays (n = 4). c, Gain of residual 53BP1 foci number per cell in 
FAPs knockdown cell cultures irradiated with 6 Gy X-rays (53BP1 foci in controls were subtracted from the total 
number of foci). d, Scatter plot of 53BP1 residual foci/cell against surviving fraction upon FAPs knockdown and 6 
Gy irradiation. Main candidates with high foci/cell and low cell survival are shown on the graph. 
 
5.1.2 Synemin modulates radiation sensitivity and DNA double strand break 
repair in HNSCC. 
Database- and software-based analyses were performed to filter the targets from the screen. 
Due to its novelty in HNSCC, synemin was chosen as the main candidate. Based on On-
comine database (https://www.oncomine.org), synemin showed an upregulation in different 
human malignancies including HNSCC compared to the corresponding normal tissues (Fig. 
5.5a). In addition, the analysis of the cancer genome atlas dataset demonstrated that syne-
min was amplified in different types of several squamous cell carcinomas, such as HPV neg-
ative HNSCC, lung squamous cell carcinomas (LUSCC) and cervix squamous cell carcino-
mas (CESCC) (Fig. 5.5b) (Network, 2015). 
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Figure 5.5: Top focal adhesion protein affecting cell survival. a, To evaluate synemin overexpression of the 
head and neck carcinomas in comparison to the corresponding normal tissue, the mRNA level was analyzed 
using Oncomine database (https://www.oncomine.org). b, DNA copy number alterations from TCGA data (Com-
prehensive genomic characterization of head and neck squamous cell carcinomas, The Cancer Genome Atlas 
Network). c, Interactome map of synemin using Cytoscape software (https://cytoscape.org/) with Reactome 
plugin. Data are represented as mean ± SD (two-sided t-test; *P<0.05, **P<0.01, ***P<0.001). 
 
Interactome prediction of the main candidates in DNA repair response using Cytoscape soft-
ware (Xue et al., 2008) with Reactome plug-in revealed synemin as a potential interactor of 
ATM and ATR (Fig. 5.5c). 
To validate the function of synemin in DNA damage repair response clonogenic 
survival and 53BP1 foci assay was carried out in a panel of ten 3D grown HNSCC cell lines 
upon synemin depletion and X-ray radiation exposure. The basal clonogenic survival, as well 
as the endogenous 53BP1 foci number, of all tested HNSCC cell lines remained unaltered 
upon synemin knockdown (Fig. 5.6a-c). 
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Figure 5.6: Synemin essentially controls cellular radiosensitivity and DSB repair. a, Immunoblots with 
knockdown efficiencies in a panel of HNSCCs. b, Normalized plating efficiency of a panel of HNSCCs upon 
synemin inhibition (n ≥ 3). c, Spontaneous foci per cell in a panel of HNSCC upon synemin inhibition (n = 3). Data 
are represented as mean ± SD (two-sided t-test; *P<0.05). 
 
Interestingly, synemin depletion led to significant radiosensitization of seven out of ten cell 
lines relative to controls (Fig. 5.7a,b). Likewise, synemin silencing elicited a significant 
increase in the number of 53BP1 foci in all HNSCC cell lines after irradiation (Fig. 5.7c,d). To 
confirm these results, SAS cells were transfected with mCherry-Synemin plasmid inducing 
overexpression of the protein (Fig. 5.7e,f). Contrary to synemin depletion, SAS cells 
overexpressing mCherry-Synemin showed a higher clonogenic survival and a reduced 
residual 53BP1 foci number after irradiation relative to the controls (Fig. 5.7g,h). 
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Figure 5.7: Synemin essentially controls cellular radiosensitivity and DSB repair. a, Clonogenic radiation 
survival of 6-Gy X-ray irradiated 3D lrECM HNSCC cell cultures after esiRNA-mediated synemin depletion (n ≥ 3) 
and b, representative phase contrast images of 3D lrECM grown cell cultures (bar, 500 µm). c, Effect of synemin 
silencing on residual 53BP1 foci in a panel of 6-Gy irradiated 3D lrECM HNSCC cell lines (n = 3) and d, corre-
sponding representative immunofluorescence images (bar, 10 µm). e, Fluorescence image of mCherry-Synemin 
positive SAS cell (bar, 10 µm). f, Immunoblotting of the mCherry-Synemin compared to the mCherry empty vec-
tor. g, Clonogenic radiation survival of mCherry-Synemin transfectants relative to mCherry controls (6 Gy X-rays) 
(n = 3). h, Residual 53BP1 foci in mCherry-Synemin transfectants exposed to 6 Gy X-rays (n = 3). Data are rep-
resented as mean ± SD (two-sided t-test; *P<0.05, **P<0.01, ***P<0.001). 
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Figure 5.8: Synemin essentially controls cellular radiosensitivity. a-d, Knockdown efficiencies using 3 differ-
ent siRNAs for synemin silencing in Cal33 and SAS cells (a,c) and survival fraction (b,d) (n = 3). Data are repre-
sented as mean ± SD (two-sided t-test; **P<0.01, ***P<0.001). 
 
Depletion of synemin by using the different siRNAs, to verify off target effects, were achieved 
in Cal33 and SAS cells upon synemin knockdown. This experiment revealed that all tested 
synemin siRNAs, led to enhanced radiosensitivity (Fig. 5.8a-d). 
To further delineate the role of synemin in radio(chemo)resistance, a platinum-based 
genotoxic substance-cisplatin that directly binds to DNA inhibiting its replication (common 
chemotherapeutical for HNSSC patients) was applied in combination with/ without X-rays 
irradiation under synemin depletion. Upon synemin depletion, cells responded to both 
treatment approaches showing significantly higher levels of residual 53BP1 foci relative to 
controls (Fig. 5.9b). In contrast, numbers of residual γH2AX and 53BP1/γH2AX colocalized 
foci did not differ when cisplatin was applied as monotherapy. The combinatorial treatment 
irradiation/cisplatin, interestingly, significantly induced residual γH2AX and 53BP1/γH2AX 
colocalized foci number (Fig. 5.9b). 
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Figure 5.9: Synemin characterization upon radiochemotherapy. a, Dose-response relationship of SAS cells 
upon cisplatin (CDDP) exposure (n = 3). b, Effect of synemin depletion on 53BP1, γH2AX and colocalized foci 
numbers upon CDDP treatment in combination with and without irradiation (n = 3). Data are represented as mean 
± SD (two-sided t-test; *P<0.05, **P<0.01, ***P<0.001). 
 
In conclusion, the intermediate filament and focal adhesion protein synemin regulates 
clonogenic survival of HNSSC through the modulation of DSB repair after irradiation and cis-
platin treatment. 
5.1.3 Analysis of synemin dynamics after irradiation 
To characterize synemin expression and its subcellular localization, immunofluorescence 
staining of synemin was performed in all tested HNSCC cell lines. Synemin was 
predominantly localized in the cytoplasmic compartment with a slight accumulation in the 
perinuclear area and the area adjacent to the cell membrane (Fig. 5.10). Remarkably, an 
exposure of HNSCC cells to X-rays significantly induced synemin expression on the protein 
level, which peaked at 1 h after irradiation and decreased back to the expression level of 
non-irradiated cells 24 h later. At the same time, immunofluorescence staining of SAS and 
Cal33 cell lines demonstrated a presence of filament-like synemin structures within 30 min 
after irradiation. These structures (Fig. 5.11a,b) further developed into a strong and stable 
network in the cytoplasm, which persisted within 6 h after X-ray exposure. In contrast, non-
irradiated cells did not reveal any complex synemin organization. Nevertheless, it is 
questionable whether the reorganization of synemin surrounding the nucleus is associated 
with its scaffold function (Fig. 5.11a-c). 
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Figure 5.10: Synemin distribution in a panel of 10 HNSCC cell lines. Immunofluorescence staining of synemin 
distribution (green) in a panel of HNSCCs. Cells were counterstained with phalloidin (red) and DAPI (blue) (bar, 
20 µm).  
 
To further investigate and validate the kinetics of synemin, a chromatin fractionation 
assay was carried out. Chromatin was fractionated into 4 fractions as followed: fraction I 
consisted solely of membrane components, fraction II was composed of cytoplasmatic 
proteins, fraction III contained nuclear protein that loosely bound to chromatin and fraction IV 
included proteins with a strong affinity to chromatin. The result indicated that synemin was 
primarily observed in the fractions I and II, with a slight accumulation in the fraction IV under 
normal condition. Interestingly, synemin increased in fraction III 1 h after irradiation (Fig. 
5.11d,e). 
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Figure 5.11: Synemin kinetics upon radiotherapy treatment. a, Subcellular localization of synemin in Cal33 
and b, in SAS at different time points post 6 Gy X-rays (co-staining with DAPI (nucleus) and phalloidin (actin)) 
(bar, 20 µm). Overview and zoom-in. c, Immunoblotting of synemin expression kinetics post 6 Gy irradiation in 
SAS cells. β-actin served as loading control. d, Immunoblots of synemin, MEK1/2 and γH2AX from the chromatin 
fractionation (I, II, III and IV fractions) samples after SAS cells were exposed or not to 6 Gy X-ray (n = 3). e, Den-
sitometries and quantification of synemin protein levels in the different fractions and after the different treatment. 
Arbitrary units (A.U.). Data are represented as mean ± SD. 
 
These data evidence that synemin might have a direct effect on the DNA repair 
process and are in line with the previous observation showing the accumulation of synemin 
in the perinuclear area. Collectively, these results suggested that synemin might play an 
essential role in cell survival after genotoxic injury as well as in the DSB repair. 
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5.2 The role of synemin in DNA repair mechanisms in HNSCCs 
5.2.1 The effect of synemin knockdown on NHEJ, HR and Alt-EJ in HNSCCs 
To investigate the role of synemin in DNA repair mechanisms, DNA repair reporter assays 
(pGC, pEJ5) were conducted to measure HR and NHEJ activity. While synemin depletion left 
HR activity unaffected, NHEJ activity was significantly impaired showing a 40% reduction 
(Fig. 5.12a-c).  
 
Figure 5.12: Synemin functions in non-homologous end joining. a, GFP-based reporter assays for HR and b, 
NHEJ. Cal33 cells stably transfected with DRGFP or pimEJ5GFP recombinant plasmids were depleted of syne-
min (n = 3). The number of GFP-positive cells was analyzed by FACS. c, Representative figures of DNA repair 
reporter assay to evaluate homologous recombination (HR) and non-homologous end joining (NHEJ) activity. pN1 
is the empty vector (pEGFP-N1) serving as positive control and I-SceI is a plasmid expressing an endonuclease 
used to generate the DSBs. The cells that have performed DNA repair will express a GFP fluorescent protein. d, 
NHEJ activity in mCherry-Synemin-overexpressing Cal33-pEJ cells (n = 3). Analysis performed by FACS as indi-
cated under (a) and (b). e, Immunoblots from synemin-depleted and 6-Gy irradiated cells showing total PARP1 
levels (n = 3). β-actin served as loading control. Fold change quantifications are shown under the respective blot. 
Data are represented as mean ± SD (two-sided t-test; ***P<0.001). 
 
Similarly, synemin overexpression strongly enhanced NHEJ activity of almost three folds 
compared to the empty vector mCherry-C1 (Fig. 5.12d). Notably and corroborating a specific 
impact of synemin on NHEJ, neither PARP1 levels (a key protein for Alt-EJ) nor HR showed 
modifications by synemin silencing in unirradiated and irradiated cells (Fig. 5.12e). To further 
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demonstrate that synemin is an essential component in the regulation of NHEJ, the expres-
sion levels of the main NHEJ associated proteins and their phosphorylated forms were 
measured i.e. DNA-PKcs, phosphorylated DNA-PKcs at serine 2056 residue (DNA-PKcs 
S2056), ATM, phosphorylated ATM at serine1891 residue (ATM S1891), and Ku70 (Fig. 5.13 
a). Western blot analysis revealed that synemin depletion decreases radiation-induced DNA-
PKcs phosphorylation at S2056, especially 1 and 2 h after irradiation. Radiation-induced 
ATM phosphorylation level at S1981 showed only a trend towards a reduction in synemin 
deficient cells as compared to the control cells. Strikingly, the level of Ku70 protein was 
gradually decreased as a function of time due to the synemin deficiency and was undetecta-
ble at 2, 6 and 24 h after irradiation (Fig. 5.13a,b). In contrast, synemin overexpression en-
hanced the expression level of phosphorylated DNA-PKcs at S2056 and Ku70 at the base-
line (0 Gy). Altogether, these data suggested that synemin might contribute to the DNA dam-
age repair via NHEJ by modulating DNA-PKcs, ATM and Ku70 functions. 
 
Figure 5.13: Synemin functions in non-homologous end joining. a, Immunoblots from synemin-depleted and 
6-Gy irradiated cells showing total and/or phosphorylation of DNA-Pkcs, ATM and Ku70. β-actin served as loading 
control. Fold change quantifications are shown under the respective blot. b, Densitometries from immunoblots 
from synemin-depleted and 6-Gy irradiated cells showing phosphorylated or total forms of DNA-PKcs, ATM and 
Ku70 (n = 4). Phosphorylation levels were calculated relative to the total amount of the respective protein. c, Im-
munoblot of DNA-PKcs and Ku70 from whole cell lysates of 6-Gy X-ray irradiated and mock-treated mCherry-
Synemin transfectants (n = 3). β-actin served as loading control. Data are presented as mean ± SD (two-sided t-
test; *P<0.05, ***P<0.001). 
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5.2.2 The effect of synemin knockdown on DNA repair kinetics in NHEJ and 
cell cycle 
As shown above, synemin might be involved in the regulation NHEJ. Therefore, on the next 
step of this study, foci kinetics of DNA-PKcs S2056 and 53BP1 were determined upon 
synemin depletion in 1-Gy irradiated cells (Fig. 5.14a-d). Intriguingly and in line with the im-
munoblotting data, a significant reduction of DNA-PKcs S2056 foci was detected in synemin-
depleted cells over 24-h observation period relative to controls (Fig. 5.14a,d). At 30 min post 
irradiation, a reduction of DNA-PKcs S2056 foci c.a. 3-4 foci/cell was observed, whereas the 
amount of 53BP1 foci was not altered. An increase in a number of 53BP1 foci in synemin 
deficient cells was found 1 h after irradiation (Fig. 5.14a,c) which could be related to the 
presence of unsolved DNA-PKcs S2056 foci at 30 min after X-ray exposure. Similar observa-
tions were made for γH2AX foci (Fig. 5.14b) which presented a lower amount of foci as com-
pared to the respective control at 30 min and 1 h after irradiation. This result might be related 
to the delayed recruitment of γH2AX foci in synemin-depleted cells, but the number of γH2AX 
foci was then significantly increased 2 h post IR. 
Since synemin is indispensable for NHEJ, cell cycle re-distribution could be attributed 
to the function of synemin. Hence, cell cycle analysis were performed upon synemin silenc-
ing in unirradiated and irradiated cells (Fig. 5.15a,b). The result indicated no connections 
between synemin and cell cycle progression.  
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Figure 5.14: Synemin functions in non-homologous end joining. a, Kinetics of 53BP1, DNA-PKcs S2056 and 
b, γH2AX foci upon synemin knockdown at different time points post 1 Gy X-rays including immunofluorescence 
images of residual 53BP1 (c) and DNA-PKcs S2056 (d) foci of synemin knockdown and control cell cultures 1 h 
after 1 Gy X-rays (bar, 10 µm). Data are presented as mean ± SD (n = 3; two-sided t-test; *P<0.05, **P<0.01, 
***P<0.001). 
 
It was observed that synemin partially interacts with chromatin, by which chromatin 
modification might be affected by the depletion of synemin. Therefore, an expression level of 
a crucial chromatin modification factor, termed heterochromatin protein 1- alpha (HP1-α), 
was determined upon synemin knockdown. The HP1-α expression level was determined by 
immunoblotting and immunocytochemical staining. In both analyses, no significant alteration 
in chromatin condensation upon synemin knockdown was observed, neither in untreated 
cells nor X-ray exposed cells. 
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Figure 5.15: Synemin effects on cell cycle. a, Cell cycle distribution of SAS cells upon synemin knockdown at 
24, 48 and 72 h post transfection b, and at 12 and 24 h post 6 Gy X-ray irradiation. Data are represented as mean 
± SD (n = 3; two-sided t-test). 
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Figure 5.16: Synemin effects on heterochromatin levels. a, Immunoblots and densitometry from synemin-
depleted and 6-Gy irradiated cells showing total HP1α levels. β-actin served as loading control. Densitometries 
are shown under the blot. b, Immunofluorescence of HP1α from synemin-depleted and 6-Gy irradiated cells and 
relative intensities for heterochromatin evaluation (bar, 10 µm). Data are represented as mean ± SD (n = 3; two-
sided t-test). 
 
This result suggests that synemin regulates DNA repair mechanism mainly through the 
phosphorylation of key DNA repair proteins leading to their recruitment to the damage sites 
independently of cell cycle and chromatin organization. 
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5.3 Synemin signaling in head and neck squamous cell carcinoma 
(HNSCC) 
5.3.1 Regulation of kinase activity by synemin  
To further unravel the molecular mechanism underlying an impaired NHEJ in synemin-
deficient cells after irradiation, a broad-spectrum kinase profiling was performed. Intriguingly, 
significant changes were found in protein kinase activities in synemin-deficient, irradiated 
cells at 1 h and 24 h after X-ray exposure (Fig. 5.17a and 5.18a). Remarkably, synemin 
knockdown alone failed to modify protein kinase profiles (Fig 5.17a and 5.18a) indicating that 
the DNA repair-co-regulating function of synemin becomes essential upon genotoxic injury. 
Based on the kinase profiling data, important DNA repair regulators c-Abl and several 
Src family members (Scr, Yes, Lck, Blk and Lyn) were identified as the top deactivated tyro-
sine kinases in synemin-deficient, 6-Gy X-ray irradiated cells compared to the respective 
controls (Fig. 5.17b and 5.18a,b). Calculating the - Δ Effect (τ24h, 6Gy - τ0Gy) (Fig. 5.18a) it is 
possible to observe the additional effects of synemin depletion on tyrosine kinases upon irra-
diation (Fig 5.17b and 5.18b). In contrast, serine/threonine kinases remained partly unaffect-
ed in synemin-depleted cells (Fig. 5.17b) apart from some CMGC (cyclin dependent kinases) 
and CAMK (calcium- and calmodulin-regulated kinases) serine/threonine kinases. Based on 
the prediction algorithm of Cytoscape and of the Group-based prediction system (GPS 3.0, 
http://gps.biocuckoo.org/) (Xue et al., 2008) database analysis, c-Abl was predicted to be 
central to components of the NHEJ and HR repair machinery. As shown before synemin 
consists of numerous amino acid residues which serve as putative phosphorylation sub-
strates for serine/threonine and tyrosine kinases (Fig. 5.17c,d). Accordingly, many kinases of 
the kinome screen with downregulated activity are predicted to phosphorylate synemin at 
different sites (Fig. 5.17c,d and 5.18a,b). In order to further investigate the underlying mech-
anism, c-Abl total protein expression was examined, as well as c-Abl phosphorylation level at 
Y412 and T715 sites which are responsible for the c-Abl kinase activity and c-Abl subcellular 
distribution respectively. Interestingly, phosphorylation at both Y412 and T715 residues was 
significantly reduced upon synemin knockdown in irradiated cells relative to controls 6 h and 
24 h after X-rays exposure, while the level of total c-Abl protein remained unchanged (Fig. 
5.19a,b). Moreover, synemin overexpression revealed a stabilized and not radiation-inducible 
Y412 phosphorylation relative to mCherry controls indicative of a dependence of c-Abl activi-
ty on synemin (Fig. 5.19c).  
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Figure 5.17: Synemin regulates tyrosine kinase activity, in particular c-Abl kinase. a, Heatmap of phosphor-
ylated peptides by tyrosine kinases of control and synemin knockdown samples before and after 1 and 24 h X-ray 
treatment (n = 3). b, Kinase family tree of down and up regulated kinases 24 h post irradiation and synemin 
knockdown. The green circle shows the tyrosine kinases. c, Predicted phosphorylation sites (Y) of synemin and 
the corresponding kinases with a prediction score greater than 5 using GPS database (GPS 3.0, 
http://gps.biocuckoo.org/). d, Predicted sites of synemin phosphorylation at Serine (S) and Threonine (T) residues 
by PIKK kinases. The table shows the amino acid position and corresponding kinases with a prediction score 
greater than 5 using GPS database (GPS 3.0, http://gps.biocuckoo.org/). 
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Figure 5.18: Synemin regulates c-Abl kinase activity. a, Heatmap of tyrosine kinase activities in cells depleted 
of synemin and exposed to 6-Gy X-ray irradiation including - Δ Effect (τ24h, 6Gy - τ0Gy) (subtraction of values ob-
tained from synemin-depleted cells 24 h post 6 Gy X-ray irradiation from non-irradiated, synemin-depleted cells). 
Kinase activity profiles were generated by PamGene Technology. b, Top affected tyrosine kinases in synemin-
depleted cell cultures 24 h post 6 Gy X-ray irradiation. X-axis indicates the τ value for each kinase (τ < 0 indicates 
reduced kinase activity relative to control). The colors of the dots indicate the specificity score. The size of the 
dots indicates the number of peptides. The Y-axis shows the overall score. c, c-Abl interactome of DNA repair 
proteins calculated by Cytoscape. 
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Figure 5.19: Synemin regulates c-Abl kinase activity. a, Immunoblot of c-Abl expression and phosphorylation 
from whole cell lysates of synemin-depleted cells and 6-Gy irradiated b, together with corresponding densitome-
tries from immunoblots showing phosphorylated forms of c-Abl (n = 4). Phosphorylation levels were calculated 
relative to the total amount of c-Abl. c, Immunoblot of c-Abl expression and phosphorylation from whole cell ly-
sates of mCherry-Synemin transfectants at different time points post 6 Gy X-ray irradiation (n = 3). β-actin served 
as loading control. Data are represented as mean ± SD (two-sided t-test; *P<0.05). 
 
Altogether, synemin seems to have a significant role in the regulation of c-Abl kinase 
activity and its localization, which could potentially associate with the regulation of DNA 
damage repair. 
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5.3.2 Synemin as upstream protein of c-Abl and DNA-PKcs 
Previous reports indicated DNA-PKcs and ATM as potential regulators of c-Abl function 
(Tang et al., 2012). As it has been shown above synemin plays a critical role in the regulation 
of c-Abl activity, however, the understanding of interconnections between synemin, c-Abl and 
DNA-PKcs requires further investigations. 
 
Figure 5.20: Synemin/DNA-PKcs/c-Abl co-control radiation survival. a, Knockdown efficiencies of single, 
double or triple esi/siRNA transfections. β-actin served as loading control. b, Plating efficiency of SAS cells upon 
single, double or triple knockdown of synemin, DNA-PKcs and c-Abl. c, 3D clonogenic radiation survival upon 
single, double and triple silencing of synemin, DNA-PKcs and c-Abl. Data are represented as mean ± SD (n = 3; 
two-sided t-test; *P<0.05, **P<0.01, ***P<0.001). 
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Figure 5.21: Synemin/DNA-PKcs/c-Abl co-control DSB repair. a, Residual 53BP1 foci per cell upon single, 
double or triple knockdown of synemin, DNA-PKcs and c-Abl in 6-Gy X-ray irradiated cells. Transfection with 
single or double non-specific siRNA was used as controls. b, Exemplary immunofluorescence images of residual 
53BP1 foci (co-staining with DAPI (nucleus)). c, γH2AX and d, 53BP1-γH2AX colocalized foci after single, double 
and triple knockdowns exposed to sham or 6 Gy X-rays. Data are represented as mean ± SD (n = 3; two-sided t-
test; *P<0.05, **P<0.01, ***P<0.001). 
 
To this end, single, double and triple knockdown of synemin, c-Abl and DNA-PKcs (Fig. 
5.20a) was performed, which revealed no significant effect on the basal survival, except for 
the combined DNA-PKcs/c-Abl silencing (Fig. 5.20b). Intriguingly, single synemin and DNA-
PKcs but not c-Abl knockdown significantly enhanced cellular radiosensitivity upon irradiation 
compared to the control cells (Fig. 5.20c). Double knockdowns of synemin/DNA-PKcs, DNA-
PKcs/c-Abl and synemin/c-Abl, as well as the triple synemin/DNA-PKcs/c-Abl knockdown, 
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demonstrated similar radiosensitizing effects as a single knockdown, indicating that all tested 
targets represent a part of one signaling pathway (Fig. 5.20c). 
To further underpin the role of synemin/c-Abl/DNA-PKcs interaction, residual 53BP1 
foci numbers relative controls were evaluated (Fig. 5.21a,b). The number of residual 53BP1 
foci were similarly increased in the single, double and triple knockdowns as compared to the 
controls (Fig. 5.21a,b). From these data, two observations could be drawn out: (i) synemin 
impacts on the functionality of c-Abl and DNA-PKcs in DSB repair and (ii) synemin, c-Abl and 
DNA-PKcs are components of the same signaling pathway. Consistently, analysis of the 
number of residual γH2AX and 53BP1/γH2AX foci showed similar results (Fig. 5.21c,d) to the 
53BP1 numbers. In conclusion, the molecular functions of DNA-PKcs and c-Abl in the DNA 
damage response depended on synemin. 
5.3.3 Synemin forms a complex together with c-Abl and DNA-PKcs 
To investigate a direct interaction between synemin, DNA-PKcs and c-Abl, immunoprecipita-
tion assays with endogenous synemin and synemin conjugated with mCherry were per-
formed. Strikingly, c-Abl and DNA-PKcs exhibited binding to synemin and synemin binding to 
c-Abl in reverse immunoprecipitations relative to IgG and mCherry controls (Fig. 5.22a-c). 
Interestingly, upon X-ray exposure, the interaction between synemin and c-Abl as well as 
DNA-PKcs was slightly decreased (Fig. 5.22a-c). To validate the result from immunoprecipi-
tation and identify the subcellular interaction site between synemin and the 2 kinases, a prox-
imity ligation assay (PLA) was performed in non-irradiated and 6 Gy X-ray treated SAS cells. 
In both cases, the interaction of c-Abl/synemin and DNA-PKcs S2056/synemin was detected 
in un- and -irradiated cells (Fig. 5.22d,e). From the PLA assay it is possible to conclude that 
synemin binds to c-Abl mainly in the cytoplasm, whereas DNA-PKcs S2056/synemin interac-
tion occurs mainly in the nucleus. Taken together, synemin was able to form a protein com-
plex together with c-Abl and DNA-PKcs independently. 
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Figure 5.22: c-Abl and DNA-PKcs forms a complex together with synemin. a, Immuno-precipitation (IP) of 
synemin 1 h post 6 Gy X-rays (n = 3). Immunoblotting shows expression of synemin, c-Abl and DNA-PKcs. b, IP 
of c-Abl 1 h post 6 Gy X-rays (n = 3). Immunoblotting shows expression of synemin and c-Abl. c, Western blots on 
immunoprecipitates from 6-Gy irradiated mCherry-SAS and mCherry-Synemin-SAS cells at 1 h post irradiation (n 
= 3). β-actin served as loading control. d, Interaction of synemin and c-Abl or e, DNA-Pkcs S2056 in unirradiated 
and irradiated cells defined by proximity ligation assay (n = 3) (bar, 10 µm). 
 
5.3.4 Synemin function is regulated by ATM kinase activity 
In order to understand whether the interaction between synemin and c-Abl/DNA-PKcs is de-
pendent on the kinase activity of these two proteins as well as ATM, a kinase essentially in-
volved in c-Abl and DNA-PKcs activation, c-Abl, DNA-PKcs and ATM, were pharmacological-
ly inhibited using imatinib (c-Abl), NU7026 (DNA-PKcs), KU55933 (ATM) prior to immunopre-
cipitation of synemin (Fig. 5.23a). Astonishingly, declined and absent binding of c-Abl under 
ATM inhibition was found in unirradiated as well as under DNA-PKcs and ATM inhibition in 
irradiated cells, respectively (Fig. 5.23a). DNA-PKcs, however, showed increasing dissocia-
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tion from synemin upon DNA-PKcsi and ATMi (Fig. 5.23a, lane 2, 3, 4). In irradiated cells, 
DNA-PKcs generally bound less to synemin (Fig. 5.23a), an interaction completely lost upon 
DNA-PKcs and ATM inhibition (Fig. 5.23a). 
To corroborate the effect of ATM on synemin, SKX, an ATM deficient squamous cell 
carcinoma cell line owing to the overexpression of miR-421 (Mansour et al., 2013) was used. 
Interestingly, the result of immunoprecipitation of synemin from SKX cells demonstrated that 
ATM does not affect c-Abl/synemin, but instead perturbed DNA-PKcs/synemin interaction 
(Fig. 5.23c). This result is partly in line with the previous observations in SAS cells treated 
with c-Abl, ATM and DNA-PKcs inhibitors. Interestingly, SKX cells expressed higher levels of 
synemin and c-Abl relative to SAS cells suggesting an activation of the by-pass mechanism 
due to ATM dysfunctionality. In further investigations, mCherry-Synemin-overexpressing SAS 
cells were treated with ATMi and irradiation. The numbers of radiogenic 53BP1 and DNA-
PKcs S2056 foci were significantly decreased upon ATMi-treatment of SAS cells 1 h after 
irradiation as compared to the DMSO-treated mCherry controls (Fig. 5.22b). At 24 h after 
irradiation, 53BP1 and DNA-PKcs S2056 foci numbers were significantly elevated due to the 
ATM inhibition which was similar to the mCherry empty vector (Fig. 5.23b). From these re-
sults, it is possible to conclude that synemin contributes to the regulation of the DNA repair 
via the ATM-dependent recruitment of 53BP1 and DNA-PKcs to the DSB site. 
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Figure 5.23: c-Abl and DNA-PKcs interaction with synemin depends on ATM kinase activity. a, IP of SAS 
cells expressing mCherry and mCherry-Synemin. Cells were treated with Imatinib, DNA-PKcsi or ATMi and ex-
posed to sham or 6 Gy X-rays. Western blots on immunoprecipitates from mCherry-Synemin-SAS cells after a 1 h 
pretreatment with imatinib, DNA-PKcsi or ATMi alone or in combination with 6 Gy X-rays. b, 53BP1 and DNA-
PKcs S2056 foci upon ATMi treatment at different time points post 1 Gy X-rays in mCherry- and mCherry-
Synemin transfectants. c, Western blots on immunoprecipitates from SAS and SKX cells 1 h after 6 Gy X-rays 
exposure. Data are represented as mean ± SD (n = 3; two-sided t-test; *P<0.05, **P<0.01, ***P<0.001; n.s., not 
significant (P≥0.05)).). 
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5.3.5 Synemin tail is phosphorylated by ATM kinase and it is essential for 
synemin function 
To determine the functional site of synemin, which essentially contributes to its function in 
DNA damage repair, two synemin constructs were designed: (i) deletion of coil-coil linker and 
tail domains; (ii) deletion of head and coil-coil linker domains (Fig. 5.24a,b). Plasmids con-
taining DNA expressing synemin variants were transfected into SAS cells, and 53BP1 and 
DNA-PKcs S2056 foci were microscopically counted. For foci assay evaluating 53BP1 and 
DNA-PKcs S2056, it was observed that the number of foci in cells expressing only the syne-
min tail (Synemin_Tail) was comparable to the cells with wild type synemin (Fig. 5.24c). In 
contrast, the construct expressing synemin head demonstrated similar effects as the mCher-
ry control plasmid (Fig. 5.24c). These data suggest that only the tail of synemin mediates the 
interactions between synemin and DNA repair proteins. 
Taking the prediction from the GSP database into account that only serine amino acid 
residues at the tail, but not at the head or coil-linker domains of synemin, are phosphorylata-
ble by ATM (Fig. 5.24a), the residual 53BP1 foci in SAS cells expressing the different syne-
min constructs upon ATM inhibition were evaluated (Fig. 5.24d). Similar to the previously 
shown result, the Synemin_Tail construct showed the same effect as mCherry-Synemin 
wildtype. As ATM kinase is inhibited, the numbers of residual foci are similar among wildtype 
and mutated constructs as well as mCherry control. Taken together, these results suggested 
that the synemin tail domain has a critical role in the DNA repair process. In addition, the 
GSP database indicated that only S421, S554, S1114, S1159 AA residues at the synemin 
tail, but none at the head or coil-linker domains of synemin can be phosphorylated by ATM 
(Fig. 5.25a). To characterize the influence of these phosphorylation sites within the synemin 
tail on DNA repair, further synemin constructs containing either tail AAs 301 to 961 (mCher-
ry-Synemin_301-961) or tail AAs 962 to 1565 (mCherry-Synemin_962-1565) were generated 
(Fig. 5.25a). Using these constructs, 53BP1 foci upon X-ray irradiation were evaluated. A 
significant increase of 53BP1 foci upon expression of mCherry-Synemin_962-1565, but not 
mCherry-Synemin_301-961 was found, indicating a potential function of S1114 and S1159 in 
DNA repair (Fig. 5.25a-c). To further prove the functionality of these serine residues, point 
mutations at the phosphorylation site of S1114 (mCherry-Synemin_S1114A) and S1159 
(mCherry-Synemin_S1159A) were introduced (Fig. 25a). 53BP1 foci quantification upon 
overexpression of these constructs revealed that the function of synemin was left unaffected 
when the S1159 was mutated, but a loss of function of synemin was observed when S1114 
was altered to alanine (Fig. 5.25b,c). These data suggest that the S1114 AA residue in the 
synemin tail is specifically required for the DNA repair function of synemin. Interestingly, this 
serine is surrounded by glutamines (Q) indicating that the AA residue sequence from 1113 to 
1115 is QSQ, for which a higher specificity for ATM phosphorylation has been demonstrated. 
Results 
83 
 
Figure 5.24: c-Abl and DNA-PKcs interaction with synemin depends on ATM kinase activity. a, Design of 
different synemin constructs. b, Immunoblotting of SAS cells transfected with different mCherry-Synemin plasmid 
constructs. c, 53BP1 and DNA-PKcs S2056 foci kinetics in 1-Gy X-ray irradiated transfectants expressing mCher-
ry-Synemin wildtype, mCherry-Synemin ΔLink-Tail, or mCherry-Synemin ΔHead-Linker (mCherry was used as 
control). d, Residual 53BP1 foci upon treatment with ATMi and 1 Gy X-rays in SAS cells expressing mCherry-
Synemin wildtype, mCherry-Synemin ΔLink-Tail, or mCherry-Synemin ΔHead-Linker (mCherry was used as con-
trol). Data are represented as mean ± SD (n = 3; two-sided t-test; **P<0.01, ***P<0.001; n.s., not significant 
(P≥0.05)). 
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Figure 5.25: Synemin depends DNA repair function depends on S1114 phosphorylation site. a, Design of 
different synemin constructs. b, 53BP1 foci kinetics in 1-Gy X-ray irradiated transfectants expressing mCherry-
Synemin wildtype, mCherry-Synemin_301-961, mCherry-Synemin_962-1565, mCherry-Synemin_S1114A, and 
mCherry-Synemin_S1159A (mCherry was used as control) and c, corresponding representative immunofluores-
cence images (bar, 20 µm). Data are represented as mean ± SD (n = 3; two-sided t-test; ***P<0.001; n.s., not 
significant (P≥0.05)). 
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Figure 5.26: Synemin’s mechanism. Under physiological condition, synemin interacts with c-Abl and DNA-PKcs 
in an ATM kinase-dependent manner. This interaction controls non-homologous end joining (NHEJ), cell survival 
and resistance to radiation. Upon synemin silencing, phosphorylation of c-Abl and DNA-PKcs is perturbed eliciting 
dysfunctionality of NHEJ and reduction of cell survival and radioresistance. A similar phenotype with lessened 
NHEJ and survival provoked by pharmacological inhibition of the ATM kinase activity presents with a dispersed 
synemin/c-Abl/DNA-PKcs protein complex.  
 
Taken together, this study showed that an ATM-dependent interaction of synemin with 
c-Abl and DNA-PKcs controls NHEJ, as well as cell survival and resistance to radiation. 
Synemin silencing perturbed c-Abl/DNA-PKcs phosphorylation and reduced cell survival and 
radioresistance by modulating the functionality of NHEJ. Similarly, pharmacological inhibition 
of ATM kinase activity hindered the complex formation of synemin/c-Abl/DNA-PKcs, reducing 
NHEJ and enhancing radiosensitization of HNSCC (Fig. 5.26). 
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6 Discussion 
Reduction of treatment resistance remains one of the major challenges for improving cancer 
patient survival. To safeguard genomic stability and cell survival, cells employ multiple com-
plex DNA repair machineries. While the application of DNA-damaging agents such as radia-
tion and chemotherapeutics are the standard approaches for cancer treatment, an addition of 
molecular targeted drugs seems to be beneficial. For instance, the combination of EGFR or 
integrins treatment with radiation on cancer cells demonstrated a more efficacious eradica-
tion of various subpopulations of therapy-sensitive and -resistant malignant cells (Harari and 
Huang, 2001; Iris Eke et al., 2010; Eke et al., 2015; Dickreuter et al., 2016; Zscheppang et 
al., 2016). Recent work has demonstrated that the two main DNA repair processes (i.e. HR 
and NHEJ) are more than just nuclear events because they are critically co-regulated by ex-
tracellular and cytoplasmic cues (Pickup et al., 2014; Mahajan and Mahajan, 2015). Numer-
ous transmembrane growth factors, adhesion receptors, cytoplasmic protein kinases, and 
adapter proteins coalesce at focal adhesions and serve as essential and powerful hubs for 
prosurvival resistance-mediating and DNA repair-modifying signal transduction (Cabodi et 
al., 2010; I. Eke et al., 2010; Vehlow and Cordes, 2013; Eke et al., 2015; Seguin et al., 2015; 
Williams et al., 2015; Dickreuter et al., 2016; Tang et al., 2016; Christmann et al., 2017; He et 
al., 2019). To gain deeper insight into the functions of focal adhesion proteins (FAP) in thera-
py resistance of HNSCC cancer cells, we employed a 3D high-throughput RNAi-based 
screen (3DHT-RNAi-S) and identified a previously uncharacterized function of an IF protein, 
synemin, in radiochemosensitivity and DNA damage repair of HNSCC cells. 
In the present work, it is shown that (1) the 3DHT-RNAi-S is a consistent and robust 
platform for the identification of novel targets; (2) the inhibition of synemin significantly in-
creases the number of radiogenic DSB and elicits radiosensitization; (3) synemin expression 
and dynamics change upon irradiation; (4) synemin affects NHEJ, but not HR and Alt-EJ, 
through the regulation of two key DNA repair proteins: DNA-PKcs and Ku70; (5) synemin 
inhibition leads to deregulated tyrosine kinase activities post X-ray exposure; (6) synemin 
regulates c-Abl tyrosine kinase activity post X-ray exposure; (7) synemin is an upstream pro-
tein of DNA-PKcs and c-Abl kinases; (8) synemin forms a complex with DNA-PKcs and c-Abl 
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in an ATM-dependent manner; (9) synemin’s function in DNA repair is limited to the tail do-
main, more specifically to the serine located at the 1114 position. 
6.1 The 3DHT-RNAi-S demonstrates as a consistent and robust 
platform for the identification of novel targets 
The 3DHT-RNAi-S provided a consistent and extensive set of data (Fig. 2a,b and 3). Previ-
ously, it has been reported that FAPs such as β1 integrin, LIMS1, FAK and FHL2 contribute 
to cancer cell therapy resistance (Eke et al., 2012; Hehlgans et al., 2012; Rossow et al., 
2015; Zienert et al., 2015). Moreover, preclinical studies reported radio-sensitization of tumor 
cells and reduces their survival upon inhibition of FAPs (e.g. β1 integrin, AKT, FAK) (Park et 
al., 2008; Eke et al., 2012b). Here, several novel candidates were identified. For example, 
silencing of Moesin and KIF-11 diminished basal clonogenicity. Moesin has a function to 
connect the major cytoskeleton structures to the plasma membrane. Thus, the inhibition of 
moesin could disrupt the adhesion of ECM to plasma membranes leading to the impairment 
in colony formation. On the other hand, KIF-11 is a motor protein required for the generation 
of the bipolar spindle during mitosis. Lack of the essential protein prohibits single cells to 
form colonies. In combination with X-ray irradiation, the main identified candidates of which 
silencing significantly enhanced cellular radiosensitivity were Parvin β, GRB7, Vinculin, Sorb-
in and SH3 domain containing 2 (SORBS2), and integrin α1, while SLC3A2 and CSRP1 re-
duced cellular radiosensitivity. Parvin β is overexpressed in colorectal cancer, and it corre-
lates with tumor progression (Bravou et al., 2015). This correlation is also true for ovarian 
serous carcinomas, where high expression of Parvin β was observed in the primary tumors 
as well as in solid metastasis (Davidson et al., 2013). GRB7 was shown to promote cancer 
cell survival and invasion in triple-negative breast cancers and cervical cancers (Ramsey et 
al., 2011; Giricz et al., 2012; Zhao et al., 2017). Vinculin expression level was reported to be 
associated with an increased tumor cell proliferation and progression in prostate and pancre-
atic cancers (Ruiz et al., 2011; WANG et al., 2012). In the case of Integrin α1, although yet to 
be studied comprehensively, it has been recently identified as a pre-malignant biomarker that 
contributes to therapy resistance and metastasis in pancreatic cancer (Gharibi et al., 2017). 
In contrast, suppression of SLC3A2 was recently reported to protect ovarian cancer cells 
from chemotherapeutics (Cui et al., 2018). 
Concurrent to the clonogenic survival assay, residual 53BP1-GFP foci were assessed 
as a readout for DSB repair capacity in unirradiated and 6-Gy irradiated 3D UTSCC15-
53BP1-GFP cell cultures upon knockdown of the 117 FAPs. Silencing of various FAPs 
caused a gain of 53BP1-GFP foci relative to controls upon X-ray treatment. FAPs that could 
be novel determinants of DSB repair showing a significant increase in residual 53BP1-GFP 
foci are indicated as follows: integrin αV, α7, α8, α11 and β8 subunits, KEAP1, LDB3, 
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TGFB1, and SDCBP. Christmann and colleagues reported that integrin αVβ3 silencing 
chemosensitized glioma cells by suppression of HR repair capacity. KEAP1 is known to 
regulate DNA repair through the interaction with PALB2, a key protein for the repair of radio-
genic DSB during HR (Pauty et al., 2014). KEAP1 regulates PALB2 during oxidative stress 
and in normal conditions PALB2 favors the sub-nuclear localization of BRCA2 and RAD51 
upon exposure to genotoxic stress (Pauty et al., 2014). Silencing of integrin α1 and α7, en-
doglin, SDCBP, KEAP1, synemin, and talin 1 concertedly enhanced radiosensitivity and 
numbers of residual DSB foci. It was reported that when negatively regulated in ovarian can-
cer, endoglin contributed to enhanced sensitivity towards chemotherapeutics to which an 
increased induction of DNA damage may be related (Ziebarth et al., 2013; Chen et al., 2014). 
The impairment of FAPs that solely led to compromised clonogenic survival (e.g. vinculin, 
parvin β, and NDEL1) suggests the link between radiosensitization effect and alternative 
mechanisms other than DNA damage repair. 
These results suggest that the perturbed functions of some FAPs significantly impacts 
both radiation survival and DSB repair. Moreover, we note that our 3D-HT-RNAi-S is a robust 
screening platform for the identification of novel potential regulators of cellular radiation sur-
vival and DSB repair. 
6.2 The inhibition of synemin significantly increases DSB numbers 
and cellular radiosensitivity 
After the screen, the top candidate proteins were filtered using Oncomine and Cytoscape 
software to evaluate their expression and interactome with DNA repair proteins. Proteins 
such as α1 integrin and synemin were selected as top candidates due to their novelty in can-
cer research. In fact, few publications in the cancer field regarding these two proteins were 
found. After the validations in different types of HNSCC, synemin resulted in a stronger and 
more promising candidate than α1 integrin. 
The type IV IF protein synemin is crucial for various cell functions and the formation of 
organs such as heart and bones (Banwell, 2001; García-Pelagio et al., 2018). The molecular 
function of synemin in cancers can differ depending on tumor entities. In glioma cells, syne-
min is overexpressed and associated with enhanced cancer cell proliferation and survival 
(Pitre et al., 2012). Likewise, synemin promotes proliferation and motility of astrocytoma cells 
(Pan et al., 2008; Skalli et al., 2013). In HNSCC, synemin demonstrated an upregulation 
compared to the corresponding normal tissues similar to gliomas and astrocytomas. Moreo-
ver, synemin was amplified in several squamous cell carcinomas such as HPV negative 
HNSCC, lung squamous cell carcinomas (LUSCC), and cervix squamous cell carcinomas 
(CESCC) (Network, 2015). Contrarily, in one study of breast cancer cells, it was shown that 
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down-regulation of synemin expression through hypermethylation of the SYNM gene led to 
an acquired migrating and highly metastatic phenotype (Noetzel et al., 2010). 
The effect of synemin inhibition on radioresistance was evaluated in a panel of ten 3D-
grown HNSCC cell lines. Synemin depletion affected neither the basal clonogenic survival of 
the ten HNSCC cell lines nor the spontaneous 53BP1 foci number at 0 Gy. In contrast, X-ray 
exposure of synemin knockdown cells showed significantly enhanced radiosensitivity and 
elicited significant elevated residual foci numbers in HNSCC cell lines. This suggests that the 
effect of synemin on DNA repair and radiosensitivity is induced upon genotoxic stress. In line 
with these results, synemin overexpression led to a higher clonogenic radiation survival as 
well as a significantly lower number of residual 53BP1 foci relative to controls. Cisplatin, a 
common chemotherapeutical for HNSSC patients was, therefore, used to further address the 
function of synemin upon genotoxic stress. Similarly, higher levels of residual 53BP1 foci 
were observed upon synemin knockdown. Interestingly, Skalli and coworkers observed that 
synemin inhibition led to a reduced clonogenicity and proliferation in glioblastoma cells. 
Hence, the intermediate filament and focal adhesion protein, synemin, was selected 
based on its novelty for imparting co-regulation of cellular radiosensitivity and DSB repair in 
HNSCC. 
6.3 Synemin expression and dynamics change upon irradiation  
Subcellular distribution of synemin remains to be understood and it may be dependent on 
tissue type and tumor entity. In fact, synemin has been identified in focal adhesion localized 
at the cell membrane. Synemin, as an IF, is also part of the cytoskeleton and, therefore, is an 
active protein in the cytosol. In HNSCC, synemin is localized cytoplasmatically with a slight 
perinuclear accumulation and a sparing of the cell membrane in HNSCC cell lines. Upon ex-
posure to X-rays, synemin expression levels increased, accompanied by a changed subcel-
lular localization from a wide cytoplasmic to more perinuclear distribution. Interestingly, 
synemin reorganized around the nucleus, forming filament-like structures. This reorganiza-
tion could be related to the involvement of IFs in a variety of mechanisms in cellular stress 
response, such as tissue repair, heat shock, antimicrobial defense, and apoptosis (Marceau 
et al., 2007; Toivola et al., 2010; Geisler and Leube, 2016). 
The function of synemin distribution around the nucleus is not clear, but it may be 
linked to its scaffolding function. In fact, synemin has been identified as a scaffolding protein 
for PKA in heart tissue (Russell et al., 2006). A few hours post irradiation, it was possible to 
observe that synemin formed a strong and stable network in the cytoplasm, in contrast to the 
un-irradiated cells which did not show an organized synemin in the cytoskeleton. From the 
chromatin fractionation assay, synemin partially interacted with chromatin, and this interac-
tion increased at 1 h post irradiation. This observation is in line with the recruitment of syne-
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min in the perinuclear area. Hence, synemin surrounding the nucleus might have a direct role 
in DNA repair mechanisms, serving as a scaffold for DNA repair molecules. 
Collectively, these results suggest that synemin, also through its inducibility and peri-
nuclear accumulation, plays an essential role in cell survival after genotoxic injury by, for ex-
ample, X-rays and cisplatin, as well as in DSB repair. 
6.4 Synemin affects the NHEJ, but not the HR and Alt-EJ, through 
the regulation of two key DNA repair proteins: DNA-PKcs and 
Ku70  
An initial piece of evidence regarding the association between a FAP and DNA repair was 
reported by Hoyt and colleagues. Culturing of murine lung endothelial cells in collagen type 
IV or laminin supplementing medium activated integrins, by which bleomycin-induced DNA 
breaks were inhibited. Thus, the activation of integrins appears to be protective against geno-
toxic damage (Hoyt et al., 1997), indicating that FAP-mediated adhesion to ECM is a crucial 
factor for DSB repair. 
In the present work, a significantly increased number of residual radiation-induced 
DSBs was observed upon synemin inhibition in HNSCC cell cultures. In addition, a functional 
analysis of DNA DSB repair by NHEJ and HR reporter assay (Bennardo et al., 2008) was 
performed. The analysis from the reporter assay revealed a significantly decreased NHEJ 
activity of ~50 %upon synemin inhibition. After radiation exposure to synemin-inhibited cells, 
changes in phosphorylation and expression of some DNA repair proteins of NHEJ such as 
DNA-PKcs autophosphorylated at serine 2056 (pDNA-PKcs S2056) and Ku70 expression 
were observed, suggesting an important role in DNA damage repair of synemin. To verify 
this result, foci assay of 53BP1, γH2AX, and DNA-PKcs S2056 was carried out. Expectedly, 
residual foci numbers as well as foci kinetics were strongly affected by the absence of syne-
min. 
Generally, it is not clear whether the reduction of 50% in protein expression or phos-
phorylation has an effect on DSB repair. If it is assumed that repair proteins in the cell are 
strongly expressed; perhaps only a complete turn off of the expression or the inhibition of 
activity leads to an actual impairment of repair. Still, the observable reductions of the DNA 
repair proteins analyzed in this work seem to highly affect not only residual foci number, but 
also the kinetics of the recruited proteins such as 53BP1, DNA-PKcs S2056, and γH2AX. 
The decreased number of pDNA-PKcs S2056 foci suggests that synemin inhibition 
may lead to impaired recruitment of DNA-PKcs at the damage sites, and the broken ends, 
therefore, cannot be processed and ligated. Nonetheless, an investigation of the expression 
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of downstream proteins in NHEJ (e.g., Artemis, XRCC4, XLF, and the ligase IV) could pro-
vide a deeper insight into the synemin function in NHEJ. 
In contrast to NHEJ, the analysis of HR activity by the reporter assay, however, did not 
reveal any changes upon synemin knockdown and radiation exposure. Because single 
strand break (SSB) repair and Alt-EJ are crucial pathways in radiation-induced DNA damage 
repair, the function of synemin in these DNA repair pathways was investigated by determin-
ing PARP-1-dependent Alt-EJ expression. PARP-1 protein levels remained unchanged upon 
synemin inhibition and radiation exposure, indicating that synemin is involved in DNA repair 
merely via NHEJ. 
A strategy to obtain radiosensitizing effects could be the combined treatment with a 
clinically available PARP inhibitor — Olaparib and synemin inhibition. Under certain condi-
tions, SSBs are converted to DSB during replication and subsequently repaired mainly via 
HR (Helleday et al., 2005; Tutt et al., 2005). Because synemin inhibition affects NHEJ, it can 
be assumed that the combined treatment with synemin and Olaparib might result in the im-
pairment of NHEJ, Alt-EJ, and SSB, diminishing the DNA damage capacity of HNSCC cells. 
Thus, cells possess solely HR to rectify damage induced by radiation, leading to a high bur-
den of DNA damage upon induction (SSB and DSB), and eventually cell death. Another 
strategy could be the implementation of CDK4/6 inhibitor LY2835219, which leads to cell 
cycle arrest in G0-G1 phase in HNSSC (Ku et al., 2016), in combination with synemin inhibi-
tion. This double treatment together with irradiation could further sensitize the tumor cells 
because G1 cells apply mainly the NHEJ machinery to repair the DSB and moreover G1 
cells are known to be more radiosensitive (Hall and Giaccia, 2012). These strategies, how-
ever, require a comprehensive study to demonstrate their clinical relevance and applicability. 
6.5 Synemin inhibition leads to a deregulated tyrosine kinase activ-
ity 24 h post X-ray exposure 
To further unravel how synemin elicits its impact on NHEJ, a broad-spectrum kinase profiling 
was performed. Intriguingly, significant changes were found in protein kinase activities upon 
irradiated synemin-depleted cell cultures after 1 h and 24 h relative to controls. Interestingly, 
synemin knockdown alone failed to modify protein kinase activities, implying that the DNA 
repair-co-regulating function of synemin becomes essential upon genotoxic injury. Synemin’s 
inhibition effect was clearly potent 24 h post X-ray. From the kinase profiling, c-Abl was iden-
tified as the top deactivated protein kinase along with members of the Scr family such as Scr, 
Yes, Lck, Blk, and Lyn in synemin-depleted, 6-Gy irradiated cells compared to controls. Vari-
ous detected tyrosine kinases are known to play a role in DNA repair such as c-Abl, EGFR, 
IGF1R, Src, Lyn, and Fyn (Mahajan and Mahajan, 2015). EGFR is a well-known tyrosine 
kinase involved in therapy-resistance processes, leading for example to radioresistance. This 
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ability could be linked to its function in the regulation of essential DSB DNA repair kinases, 
such as ATM and DNA-PKcs (Lee et al., 2015; Teng et al., 2015). But its task is not limited to 
DSB; it is also involved in mismatch repair through the regulation of PCNA and also plays a 
role in chromatin modulation by affecting H4 phosphorylation (Chou et al., 2014; Ortega et 
al., 2015). IGF1R kinase has been recognized as necessary for the translocation of Rad51, a 
key HR protein. Src terminates DNA damage response signaling by controlling ATR and 
Chk1 kinases (Fukumoto et al., 2014). Regarding Lyn, it was demonstrated that upon irradia-
tion exposure, it forms a complex with CDK1, a key protein for cell cycle regulation 
(Kharbanda et al., 1996). Furthermore, Lyn activates DNA-PKcs and PKCδ, these two pro-
teins are directly involved in DNA repair processes, and their malfunction can lead to lethal 
effects to the cells (Kumar et al., 1998; Yoshida et al., 2002). In contrast to tyrosine kinases, 
serine/threonine kinases remained partly unaffected in synemin-depleted cells apart from 
some CMGC (cyclin-dependent kinases) and CAMK (calcium- and calmodulin-regulated ki-
nases) serine/threonine kinases. Altogether, these results show that synemin may indirectly 
regulate the DNA repair machinery through the modulation of important tyrosine kinases in-
volved in DNA repair processes. 
6.6 Synemin regulates c-Abl tyrosine kinase at 6 and 24 h post X-
ray exposure 
The non-receptor tyrosine kinase c-Abl was identified as the top deactivated protein kinase 
upon synemin knockdown and irradiation. c-Abl is involved in several regulatory functions 
(e.g. cell proliferation, differentiation, adhesion, migration, and DNA-repair (Plattner et al., 
1999; Hantschel and Superti-Furga, 2004)). Due to the pro-survival functions of c-Abl, altera-
tion of c-Abl kinase signaling might contribute to a more aggressive tumor phenotype 
(Srinivasan and Plattner, 2006). Thus, c-Abl has been considered as a potential therapeutic 
target for cancer treatment (Ren, 2005). A number of studies have reported an intricate 
communication between the tyrosine c-Abl and several DNA repair proteins. In fact, the mo-
lecular function of c-Abl in DNA-repair machinery has been proposed, including DNA-PKcs, 
ATM, BRCA1, and RAD51 (Jin et al., 1997; Shaul and Ben-Yehoyada, 2005). The depend-
ence of c-Abl activity on synemin was then further investigated to understand the underlying 
mechanisms. Firstly, c-Abl total protein expression was examined, as well as its phosphory-
lation sites Y412 and T715 associated with c-Abl kinase activity and the distribution of c-Abl 
in different cell compartments. Without changes in the c-Abl protein level, both Y412 and 
T715 demonstrated a significant reduction upon synemin removal in irradiated cells relative 
to controls over the 24-h observation period. During the DNA damage response, c-Abl disso-
ciates from cytoplasmatic proteins, such as 14-3-3, and shuttles into the nucleus to interact 
with various DNA repair proteins (Yoshida et al., 2005). Despite the shuttling from the cyto-
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plasm to the nucleus not being investigated, it was observed that T715 phosphorylation, 
which dictates the distribution of c-Abl in the cell, was affected by synemin inhibition. It is 
possible that the decreased T715 phosphorylation leads to an impaired redistribution of c-Abl 
upon synemin knockdown, which prohibits the relocation of c-Abl leading to a disruption of 
the kinase activity of c-Abl. This observation indicates a possible function of synemin as a 
cytoplasmic carrier or scaffold for c-Abl. Altogether, synemin appears to have a significant 
role in the regulation of c-Abl kinase activity and its localization, which could potentially asso-
ciate with the regulation of DNA damage repair. 
6.7 Synemin forms a complex with DNA-PKcs and c-Abl in an ATM-
dependent manner 
While other tyrosine and serine/threonine kinases demonstrated alterations in the absence of 
synemin, the most intriguing observation was the identification of a protein complex com-
posed of synemin, c-Abl, and DNA-PKcs, being critical for DSB repair and clonogenic radia-
tion survival. Interestingly, the DNA-PKcs single knockdown and the DNA-PKcs/synemin 
double knockdown, but not the c-Abl single knockdown, resulted in reduced survival upon 
treatment and an increased residual DSB foci number. This finding suggests synemin to be 
hierarchically upstream of c-Abl and DNA-PKcs. Synemin, as other IFs, is overexpressed in 
different human malignancies, contributing to a more aggressive phenotype (Quick et al., 
2015; Parlakian et al., 2016). In breast cancer, synemin expression is modified by aberrant 
promoter methylation and correlates with early relapse (Noetzel et al., 2010). In glioblastoma, 
synemin controls cell proliferation through the AKT pathway by antagonizing PP2A (Pitre et 
al., 2012). Contrarily, a down-regulation of synemin fails to alter the stability of the cytoskele-
ton in human hepatocellular carcinomas, indicating the tissue specificity and the multifunc-
tionality of synemin (Liu et al., 2011). Synemin has been described as a bona fide IF protein 
according to its AA sequence, with an inability to self-assemble into IFs. The unique biophys-
ical properties determine synemin’s protein interaction abilities with either the IF proteins vi-
mentin and desmin or other proteins for facilitating the assembly of dynamic and content-
specific cytoarchitecture- and stress response-related interactomes (Bilak et al., 1998). In 
line with these results, c-Abl and DNA-PKcs were precipitated by synemin with/-out X-ray ex-
posure. 
Further experiments using pharmacological inhibitors for c-Abl and DNA-PKcs corrobo-
rated these findings. Application of an ATM inhibitor revealed the dependence of the syne-
min/c-Abl/DNA-PKcs protein complex formation on ATM kinase activity both in absence and 
presence of radiogenic genotoxic injury. Using the ATM deficient cell line SKX, the interac-
tion of synemin with c-Abl was conserved, independently of the ATM status. The interrelation 
between DNA-PKcs and synemin, however, seemed to rely on ATM as in the SAS cell line. 
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In conclusion, the complex formation between synemin and DNA-PKcs relies on ATM kinase 
activity independently of the cell line. 
6.8 Synemin’s function in DNA repair is limited to the tail domain, 
more specifically to the Serine located in the 1114 position 
Due to synemin interaction with DNA-PKcs being highly dependent on ATM kinase activity, 
synemin may possess ATM kinase substrate. Thus, potential phosphorylation sites of syne-
min were investigated. Firstly, a computational prediction of phosphorylatable AA residues of 
synemin using the GPS database (Xue et al., 2008) was carried out. Intriguingly, the predic-
tion from the GSP database indicated that Serine 421, 554, 1114, 1159 residues located at 
the synemin tail, but none at the head or coil-linker domains of synemin, are phosphorylata-
ble by ATM. To confirm the prediction and the hypothesis regarding the ATM-dependence, 
cells containing different constructs of synemin (i.e., a head-linker- and a linker-tail-depleted, 
as well as a wildtype) were used. From the outcome, it is suggested that the tail of synemin 
essentially contributes to DSB repair in an ATM-dependent manner. Similarly to synemin, the 
intermediate filament vimentin is a target of DNA-PKcs upon genotoxic stress (Kotula et al., 
2013). Vimentin is phosphorylated at serine 459 by DNA-PKcs, leading to a higher cellular 
adhesion and migration ability. 
The role of the tail in IFs is not clearly understood, whereas the head and the coil-coil 
domains are necessary for filament formation. Besides the unnecessity of the tail in the for-
mation of filament, it contains important information. Synemin’s tail, compared to other IFs, is 
considerably larger, suggesting its function beyond typical IF activity. To characterize the role 
of these phosphorylation sites at the synemin tail for DNA repair, synemin constructs contain-
ing either tail AAs 301 to 961 or tail AAs 962 to 1565 were generated. The analysis of 53BP1 
repair foci upon X-ray irradiation revealed a significant increase of 53BP1 foci in cells ex-
pressing the anterior, but not the posterior, part of the tail, indicating a potential engagement 
of S1114 and S1159 for DNA repair. To further demonstrate the functionality of these serine 
residues, point mutations preventing phosphorylation of those serines were introduced. Ser-
ine 1114 AA residue at the synemin tail was found to be essential for the repair of radiogenic 
DSBs. Interestingly, this serine is surrounded by glutamines (Q), indicating that the AA resi-
due sequence from 1113 to 1115 is QSQ, for which a higher specificity for ATM phosphoryla-
tion has been demonstrated (Sampietro et al., 2018). 
 
In summary, these results suggest a critical role of synemin in the radiochemo-
resistance of HNSCC cells through its participation in NHEJ-mediated DSB repair. Synemin 
seems to serve as a scaffold protein for c-Abl and DNA-PKcs that co-determines DSB repair 
dependent on ATM. These findings shed further light on the complexity of DSB repair by 
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supporting the concept of cytoarchitectural elements as key co-regulators of nuclear events 
such as DNA damage repair. 
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7 Summary 
Background: Therapy resistance is a great challenge in cancer treatment. Among numerous 
factors, cell adhesion to extracellular matrix is a well-known determinant of radiochemo-
resistance. It has been shown that targeting focal adhesion proteins (FAPs), e.g. β1 integrin, 
enhances tumor cell radio(chemo)sensitivity in various entities such as head and neck 
squamous cell carcinoma (HNSCC), lung carcinoma, glioblastoma, breast carcinoma and 
leukemia. Previous studies demonstrated a functional crosstalk between specific FAPs and 
DNA repair processes; however, the molecular circuitry underlying this crosstalk remains 
largely unsolved. Hence, this study in HNSCC aimed to identify alternative FAPs associated 
with DNA damage repair mechanisms and radioresistance. 
Materials and Methods: A novel 3D High Throughput RNAi Screen (3DHT-RNAi-S) using 
laminin-rich extracellular matrix (lrECM) was established to determine radiation-induced re-
sidual DNA double strand breaks (DSBs; foci assay) and clonogenic radiation survival. In the 
screen, we used UTSCC15 HNSSC cells stably expressing the DSB marker protein 53BP1 
tagged to pEGFP. Validations were performed in 10 additional HNSCC cell lines (Cal33, 
FaDu, SAS, UTSCC5, UTSCC8, UTSCC14, UTSCC15, UTSCC45 and XF354fl2) grown in 
3D lrECM. Immunofluorescence staining, immunoblotting, chromatin fractionation were uti-
lized to evaluate protein expression, dynamics and kinetics post irradiation. Investigations of 
molecular mechanisms of DNA repair and radio(chemo)resistance employed DSB repair re-
porter assays for non-homologous end joining (NHEJ) and homologous recombination (HR), 
cell cycle analysis, chromatin fractionation levels evaluation and kinase activity profiling 
(PamGene) upon protein knockdown in combination with/-out X-ray exposure. Foci assay 
and clonogenic survival assay were performed after single or multiple knockdowns of syne-
min and associated proteins such as DNA-PKcs and c-Abl. Protein-protein interactions be-
tween synemin and associated proteins were determined using immunoprecipitation and 
proximity ligation assay. Mutant/depletion constructs of synemin (ΔLink-Tail, ΔHead-Link, 
Synemin_301-961, Synemin_962-1565, S1114A and S1159A) were generated in order to 
identify essential synemin’s sites controlling DNA repair functions. 
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Results: Among the targets found in the 3DHT-RNAi-S, synemin was one of the most prom-
ising FAP candidates to determine HNSCC cell survival and DNA damage repair. Synemin 
silencing radiosensitized HNSCC cells, while its exogenous overexpression induced radio-
protection. Radiation induced an increased synemin/chromatin interaction and a marked ac-
cumulation of synemin in the perinuclear area. Intriguingly, synemin depletion elicited a 40% 
reduction in NHEJ activity without affecting HR or Alt-EJ. In line, ATM, DNA-PKcs and c-Abl 
phosphorylation as well as Ku70 expression strongly declined in synemin depleted and irra-
diated cells relative to controls, whereas an opposite effect was observed under synemin 
overexpression. Single, double and triple depletion of synemin, DNA-PKcs and c-Abl resulted 
in a similar radiosensitizing effect and DSB levels as detected upon single knockdown of 
synemin, describing its upstream role. In kinome analysis, tyrosine kinases showed signifi-
cantly reduced activity after synemin silencing relative to controls. Furthermore, immunopre-
cipitation assays revealed a protein complex formed between synemin, DNA-PKcs and c-Abl 
under pre- and post-irradiation conditions. This protein complex dispersed when ATM was 
pharmacologically inhibited, implying synemin function to be dependent on ATM kinase activ-
ity. By means of the different mutation/deletion constructs of synemin, the phosphorylation 
site at serine 1114 located on the distal portion of synemin’s tail was identified as essential 
protein-protein interaction site for synemin’s function in DNA repair. 
Conclusions: The established 3DHT-RNAi-S provides a robust screening platform for identi-
fying novel targets involved in therapy resistance. Based on this screen and detailed mecha-
nistic analyses, the intermediate filament synemin was discovered as a novel important de-
terminant of DNA repair, tyrosine kinase activity and radiochemoresistance of HNSCC cells. 
These results further support the notion that DNA repair is controlled by cooperative interac-
tions between nuclear and cytoplasmic proteins. 
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8 Zusammenfassung 
Hintergrund: Die Therapieresistenz ist eine große Herausforderung in der Krebstherapie. 
Neben zahlreichen Faktoren ist die Zelladhäsion an die extrazelluläre Matrix eine bekannte 
Determinante der Radiochemoresistenz. Es wurde gezeigt, dass das Targeting fokaler Ad-
häsionsproteine (FAPs), beispielsweise das β1-Integrin, die Radiosensibilität bei verschiede-
nen Entitäten wie Plattenepithelkarzinomen des Kopfes und Halses (HNSCC), Lungenkarzi-
nom, Glioblastom, Brustkarzinom und Leukämie erhöht. Frühere Studien zeigen ein funktio-
nelles Zusammenspiel von spezifischen FAPs und DNA-Reparaturprozessen. Die molekula-
ren Mechanismen, die diesem Zusammenspiel zugrunde liegen, sind jedoch noch weitge-
hend unbekannt. Ziel dieser Studie in HNSCC war es, alternative FAPs zu identifizieren, die 
mit DNA-Reparaturmechanismen und Strahlenresistenz zusammenhängen. 
Material und Methoden: Ein neuartiges 3D-Hochdurchsatz-RNAi-Screen (3DHT-RNAi-S) 
wurde unter Verwendung einer lamininreichen extrazellulären Matrix (lrECM) etabliert, um 
strahlungsinduzierte residuelle DNA-Doppelstrangbrüche (DSBs; Foci-Assay) und klonoge-
nes Zellüberleben zu bestimmen. In diesem Screen wurden UTSCC15-HNSSC-Zellen, die 
das mit pEGFP markierte DSB-Markerprotein 53BP1 stabil exprimieren, verwendet. Validie-
rungen wurden in 10 weiteren HNSCC-Zelllinien (Cal33, FaDu, SAS, UTSCC5, UTSCC8, 
UTSCC14, UTSCC15, UTSCC45 und XF354fl2) durchgeführt, die in 3D-lrECM kultiviert 
wurden. Immunfluoreszenzfärbung, Immunoblotting und Chromatinfraktionierung wurden 
angewendet, um Proteinexpression, Dynamik und Kinetiken nach Bestrahlung zu beleuch-
ten. Um die molekularen Mechanismen von DNA-Reparatur und Radio(Chemo)resistenz zu 
untersuchen, wurden DSB-Repair-Reporter-Assays für nicht-homologes End-Joining (NHEJ) 
und homologe Rekombination (HR), Zellzyklusanalyse, Auswertung der Chromatinfraktionie-
rungsniveaus und Kinase-Aktivitäts analyse (PamGene) nach Protein-Knockdown in Kombi-
nation mit Röntgenstrahlung eingesetzt. Foci-Assay und klonogener Überlebensassay wur-
den nach Einzel- oder Multi-Knockdowns von Synemin und zugehörigen Proteinen wie DNA-
PKcs und c-Abl durchgeführt. Protein-Protein-Wechselwirkungen zwischen Synemin und 
assoziierten Proteinen wurden mittels Immunpräzipitation und Proximity-Ligation-Assay be-
stimmt. Um essentielle Regionen in Synemin zu identifizieren, die die DNA-Reparatur regu-
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lieren, wurden Konstrukte von Synemin mit unterschiedlichen Mutationen/Deletionen (ΔLink-
Tail, ΔHead-Link, Synemin_301-961, Synemin_962-1565, S1114A und S1159A) hergestellt. 
Ergebnisse: Unter den im 3DHT-RNAi-S untersuchten Proteinen war Synemin einer der 
vielversprechendsten FAP-Kandidaten zur Bestimmung des Überlebens von HNSCC-Zellen 
und der Reparatur von DNA-Schäden. Das Ausschalten der Synemin-Expression radiosen-
sibilisierte HNSCC-Zellen, während die exogene Überexpression eine Radioprotektion indu-
zierte. Die Strahlung führte zu einer erhöhten Synemin/Chromatin-Wechselwirkung und einer 
deutlichen Akkumulierung von Synemin im perinukleären Bereich. Interessanterweise führte 
das Ausschalten von Synemin zu einer Verringerung der NHEJ-Aktivität um 40%, ohne dass 
dies Auswirkungen auf HR oder Alt-EJ hatte. In der Folge sank die Phosphorylierung von 
ATM, DNA-PKcs und c-Abl sowie die Ku70-Expression in Synemin-defizienten und bestrahl-
ten Zellen im Vergleich zu den Kontrollen stark ab, während bei Synemin-Überexpression ein 
gegenteiliger Effekt zu beobachten war. Einzel-, Doppel- und Dreifachdepletion von Sy-
nemin, DNA-PKcs und c-Abl führte zu ähnlichem Ausmaß an Strahlungssensibilisierung und 
DSB-Anzahl im Vergleich zum Einzel-Knockdown von Synemin, was dessen übergeordnete 
Rolle zeigt. In der Kinomanalyse zeigten Tyrosinkinasen im Vergleich zu den Kontrollen eine 
signifikant verminderte Aktivität nach Synemin silencing. Darüber hinaus identifizierten Im-
munpräzipitationsassays einen Proteinkomplex zwischen Synemin, DNA-PKcs und c-Abl vor 
und nach Bestrahlung. Dieser Proteinkomplex wurde aufgespalten, als ATM pharmakolo-
gisch inhibiert wurde. Die deutet an, dass die Synemin-Funktion von der ATM-Kinaseaktivität 
abhängt. Unter Verwendung unterschiedlich mutierter Konstrukte von Synemin wurde die 
Phosphorylierungsstelle an Serin 1114 am distalen Teil des Synemin-Schwanzes als essen-
tielle Protein-Protein-Interaktionsstelle identifiziert, welche Synemins Funktion in der DNA-
Reparatur kontolliert. 
Schlussfolgerungen: Der etablierte 3DHT-RNAi-S bietet eine robuste Screening-Plattform 
zur Identifizierung neuartiger Zielproteine, die an der Therapieresistenz beteiligt sind. Basie-
rend auf Screening und detaillierten mechanistischen Analysen wurde das Intermediärfila-
mentprotein Synemin als eine neue wichtige Determinante von DNA-Reparatur, Tyrosinkina-
seaktivität und Radioresistenz von HNSCC-Zellen entdeckt. Diese Ergebnisse stützen zu-
dem die Hypothese, dass die DNA-Reparatur durch kooperative Wechselwirkungen zwi-
schen nuklearen und zytoplasmatischen Proteinen kontrolliert wird. 
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